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Bacillus Calmette-Guérin (BCG) immunotherapy for superficial bladder cancer is the 
most successful example of immunotherapy for human malignancies. However much 
is still unknown about its mechanisms of action – the clinical regimens used are 
empirical and frequently cause morbidity. This work investigated the local 
immunopotentiation in the bladder to intravesical BCG, using a variety of 
immunological techniques, including urinary cytokine assays, immunohistochemistry, 
in vitro bladder cancer cell line monolayer and multicellular microspheroid culture and 
LAK cell experiments, scanning electron microscopy and a clinical trial using a novel 
combination of interferon alpha and BCG, to explore the mechanisms of action of 
BCG immunotherapy. 
We have developed a reliable protocol for measuring cytokines in the urine after 
intravesical BCG instillation because cytokines are very unstable in this environment. 
We discovered that in addition to immune cells, bladder cancer cells and normal 
urothelium also produce cytokines and adhesion molecules, constitutively and on 
stimulation with BCG, both in vitro and in vivo. Activation of the cellular immune 
response responsible for the anti-tumour effects are enhanced and possibly even 
dependent on these immunomodulators. The pattern of cytokine production also varies 
between responders and nonresponders; the TH1 cytokines, IL-2 and IFNγ are 
potential prognostic markers to distinguish between these two groups. 
 
We found that BCG induces a mixed Th1 and Th2 cytokine response, with a 
predomination of TH1 cytokines. The addition of interferon alpha to BCG induces 
 xvii
more urinary interferon gamma production, a cytokine known to increase the TH1 
cellular immune response and possibly contribute to better anti-tumour efficacy.  
 
As BCG invokes an immunological response, dose and schedule are important in 
preventing overstimulation, which may lead to tolerance to BCG antigen. Indeed, non-
responders did not display immunological memory for BCG when rechallenged. 
Booster instillations invoke a secondary immune response and are probably a better 
method for inducing persistent immunoactivation than a prolonged induction course of 
BCG.  
 
Dose reduction reduces the toxicity of BCG. IFNα does not increase the toxicity of 
BCG immunotherapy. IFNα in combination with low dose BCG has superior efficacy 
to standard dose BCG immunotherapy. The combination appears to have amongst the 
best results reported to date for BCG immunotherapy, even when compared with more 
intensive schedules of BCG alone, but these results need to be confirmed in a larger 
trial. It is possible that the combination of IFNα and low dose BCG in the “6+3” 
schedule used in this study could become the new standard in immunotherapy for 













Bladder cancer is a spectrum of superficial, invasive and metastatic disease. Each differs 
in natural history and prognosis and consequently, in primary management. For 
superficial tumours, the goals of management are prevention of recurrence and 
progression; for muscle-invasive disease, the goals become survival and improvement in 
quality of life. 
1.1 Epidemiology 
Incidence 
Cancer of the urinary bladder is the 9th most common cancer worldwide representing 
3.2% of the total cancer burden (Parkin et al 1999), with an estimated total of 261,000 
incident cases and 114,000 deaths in 1990 (Pisani et al 1999). As median survival for 
bladder cancer exceeds 10 years, its prevalence is approximately 10 times its incidence. 
This, compounded by its recurrent nature, makes bladder cancer one of the costliest 
cancers today (Riley et al 1995). 
Geographical distribution 
There are wide geographical differences in incidence rates with the highest rate in males 
of 34.0 per 100,000 seen in Trieste, Italy. High incidence rates are also seen in white 
populations in the US, the Basque region in Spain and in Denmark. The high incidence 
of bladder cancer seen in the Middle East and Africa are associated with Schistosoma 
hematobium infections and are usually squamous carcinomas rather than the transitional 
cell carcinomas seen elsewhere (Bedwani et al 1998). 
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In Singapore, bladder cancer is the 7th most common cancer in males with an age-
standardized incidence rate per 100,000 (ASR) of 7.2 compared with 1.9 in females.  
These rates are relatively low compared with the incidences in some other parts of Asia, 
notably Hong Kong (ASR 14.5 per 100 000 per year). The ASR has increased by 2.3% 
over a 22-year period between 1968 and 1992 (Chia et al 1996). The ASR is highest in 
Chinese males (7.7) compared with Malay males (7.1) and Indian males (4.2). 87% of 
the cases were transitional cell carcinomas, similar to findings in the West. 
 
 




Age and incidence 
Bladder cancer is uncommon in men aged less than 30 years and women aged less than 
40. The age–specific incidence increases from the age of 50 in Singapore, similar to 
elsewhere (Fig. 1) (Chia et al 1996). 
Gender differences 
The 2-4 times lower incidence of bladder cancer in women relative to men is consistent 
worldwide. Even in the absence of known carcinogenic factors, the risk of bladder 
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cancer for men is almost 3 times higher in men than in women (Hartge et al 1990). Also, 
parous women are at decreased risk relative to nulliparous women (OR = 0.67, 95% CI = 
0.44-1.00), after adjustment for age, tobacco use and previous bladder infection (Cantor 
et al, 1992). Why this is so, is unknown. 
1.2 Etiology 
Tobacco smoking 
There is a strong and well-established association between bladder cancer and smoking. 
In different regions of the world, smoking accounts for 33% to 50% of cancers among 
men and about 25% of that among women (Silverman et al 1992; Parkin et al 1994). 
The relative risk in smokers is from 2 to 5 (Howe et al 1980; Cole et al 1971). The dose 
and duration of smoking, depth of inhalation, age of initiating smoking and type of 
tobacco have all been shown to influence the risk of developing bladder cancer (Steineck 
et al 2001). Several studies have shown an increased incidence of p17 and p53 genetic 
mutations in bladder cancers of smokers (Zhang et al 1994; Uchida et al 1995). 
Compounds associated with an increased risk of bladder cancer include aromatic amines 
(arylamines) and polycyclic aromatic hydrocarbons (e.g. 2-naphthyline, 4-
aminobiphenyl, benzene, benzidine, benzopyrene etc.) commonly found in tobacco 
smoke or exhaust gases from combustion engines (Steineck, 2001) 179.  
Carcinogens may be genotoxic, non-genotoxic or cause epigenetic changes (MacLeod et 
al 1996)126. These carcinogens or their metabolites, are electrophilic and bind to 
electron-rich nucleic acids or proteins to form adducts or cause mutagenesis (Talaska et 
al 1991; Wormhoudt et al 1999). Interestingly, neither arylamines nor polycyclic 
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aromatic hydrocarbons are direct carcinogens and it is their metabolites which are 
carcinogenic (Theodorescu & See, 2001). Foreign lipophilic compounds are converted to 
hydrophilic compounds, which are more readily excreted. In the case of arylamines, the 
first step is N-oxidation catalysed by hepatic cytochrome P450 1A2 isoenzyme (Butler et 
al 1989). The resulting metabolites, hydroxylamines, are active compounds, which bind 
to hemoglobin or form glucuronide conjugates and are excreted in the urine. 
Hydroxylamines are hydrolysed in the acidic urinary environment, allowing formation of 
adducts to nucleophilic sites in transitional bladder epithelium. Subjects with mutations 
in the promoter region of the CYP1A gene have increased transcription rate leading to 
increased production of these highly reactive metabolites. This mutation occurs more 
frequently in patients with bladder cancer (OR 1.54, CI 2.99-4.11) (Horn et al 2003). 
Fortunately, arylamines can be detoxified more safely by N-acetylation. Two 
isoenzymes of N-acetyltransferase, NAT 1 and NAT 2 catalyze this reaction. A single 
polymorphic gene encodes NAT2, with individuals having any two of several mutant 
alleles displaying a slow acetylator phenotype.  Slow acetylators are also at increased 
risk of developing bladder cancer (OR 1.88) (Johansson and Cohen, 1997).  
Metabolites of polycyclic aromatic hydrocarbons and some arylamines may undergo 
detoxification by conjugation to glutathione (Bell et al).  Heterologous carriers of the 
null phenotype for GSTM1 have an increased risk of developing bladder cancer (OR 
3.54, 95%CI, 2.99-4.11) (Horn et al 2003) (Fig. 1). 
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Fig. 2. Hypothetical model of carcinogen activation and detoxification. Note the 
resulting cellular consequences in (A) patients with normal detoxification, and (B) in 
individuals with abnormal detoxification mechanisms. Abbreviations: CYP1A2, hepatic 
cytochrome P450 1A2; NAT 2, N-acetyltransferase 2; GST-M1, glutathione S 
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Interestingly, lifestyle studies appear to support this model. Many carcinogens are 
lipophilic and may be stored in animal fat. Dietary factors associated with greater risk 
include fried meats and animal fat (Steineck et al 1990). Also, drinking more fluids (2l 
or more) decreases risk of bladder cancer, perhaps by decreasing concentration of 
carcinogenic metabolites and increasing transit time for urine (Michaud et al 1999a). A 
high intake of cruciferous vegetables may also decrease risk of developing bladder 
cancer (Michaud et al 1999b). Also, ingestion of live lactic acid bacteria (lactobacillus), 
which replaces carcinogen-producing colonic bacteria and may additionally stimulate 
interferon production, has been shown to reduce recurrence rates in some patients with 
superficial bladder cancer (Aso et al 1992). 
1.3 Genetic basis of bladder cancer 
The exact genetic events leading to bladder cancer are unknown but they appear to be 
multiple and involve activation of oncogenes or loss of tumour suppressor genes, giving 
rise to abnormal gene expression (Olumi et al 1990). A number of specific genes are 
known to be mutated by chemical carcinogens. Two of these genes, HRAS and p53 have 
been implicated in bladder cancer. Approximately 40% of bladder tumours have HRAS 
codon 12 mutations (Czerniak et al 1992). Mutations in p53 occur in up to 40% of 
bladder tumours (Sidransky et al 1991). p53 has important regulatory roles in cell 
division (see below) and p53 mutations may be important in both transformation and 
progression (Simoneau et al 1994; Esrig et al 1994). 
In bladder cancer, alterations have been observed in chromosomes 1, 5, 8, 11 (Tyrkus et 
al 1992; Vanni et al 1988; Atkin et al 1986), 7 (Babu et al 1987; Atkin et al 1993), 9 
(Gibas et al 1984; Atkin et al 1985), 13 (Gibas et al 1984), 17 (Chaturvedi et al 1997; 
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Pycha et al 1998) and 18 (Hopman et al 1989) and appear to correlate with 
tumorigenesis and progression. Microsatellite instability has also been observed in 
bladder tumours (Christensen et al 1998). 
Loss of heterozygosity in chromosome 9 occurs in 43% of bladder tumours.  (Van 
Tilborg et al 1998).  A tumour suppressor gene CDKN2A:p16 resides in the 9p21 region 
of this chromosome. It encodes p16, a cyclin dependent protein kinase, one of an 
important group of cell cycle inhibitory molecules (see Fig 1.1). p16 together with p15 
inhibit phosphorylation of the retinoblastoma protein (Rb), thereby inhibiting the cell 
cycle. Loss of either of these genes can result in uncontrolled growth. The loss of p16, 
often accompanied by a loss of p15, occurs in up to 40% of bladder tumours (Gruis et al 
1995). As cancer is a disease characterized by disordered growth, it is not entirely 
surprising that genes that control cell division and apoptosis are often altered or lost (Fig. 
2). 
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 Fig. 3(A). Schematic representation of cell cycle phases  
Mitogens drive quiescent cells into the cell cycle phase and antimitogenic signals can 
drive cells into a quiescent phase. Once a cell passes the restriction point (R), it is 
committed to progress through S phase, even in the absence of mitogenic signals. The 
DNA is replicated in S phase, and the chromosomes are segregated in mitosis. Cell cycle 




























































Fig. 3(B). Schematic representation of changes in cyclins and cdks through the cell 
cycle  
Synthesis of D-type cyclins is stimulated by growth factor signals in the G1 phase of the 
cycle and associate primarily with cdks 4 and 6. Cdk inhibitors p21 and p27 can affect 
cdk activity and in the G1 phase of the cycle, can arrest cells prior to phosphorylation of 








p53 codes a 53kDa phosphoprotein with DNA-binding properties. Its functions include 
gene transcription, monitoring of the fidelity of DNA synthesis and apoptosis (Kastan 
MB, 1997). Mutations in p53 would confer a selective growth advantage. p53 may be 
involved in both tumorigenesis and progression of transitional cell carcinomas. A model 
has been proposed for two pathways leading to the development of superficial bladder 
tumours (Fig. 4). This model postulates that chromosome 9 alterations in normal cells 
leads to papillary superficial TCC while p53 mutations lead to carcinoma in situ 
(CIS/Tis). Both p53 and chromosome 9 losses can play complementary roles further 
downstream in tumour progression. 
Fig. 4. Pathways of development and progression in bladder cancer 
New correlations between clinical observations and molecular mechanisms. (From Jones 
and Droller 1993). 98 
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1.4 Clinical issues 
1.4.1 Histology 
Urothelial carcinoma (transitional cell carcinoma) comprises more than 90% of all cases, 
with squamous cell carcinomas and adenocarcinomas comprising approximately 3-8% 
and 1% respectively. Squamous cell carcinomas are often associated with chronic 
inflammation, most frequently with Schistosoma hematobium infections, bladder stones 
and permanent indwelling catheterization and adenocarcinomas with malignant 
transformation in the urachal remnant. Both are very different in their natural history and 
management from urothelial carcinomas and will not be discussed further in this thesis. 
Urothelial carcinomas may arise anywhere along the collecting system of the genito-
urinary tract with more than 90% occurring in the bladder, 8% in the renal pelvis and 2% 
in the ureter or rarely, the proximal two-thirds of the urethra (National Board of Health 
and Welfare: Cancer Incidence in Sweden in 1985. Stockholm: National Board of Health 
and Welfare, 1989 as quoted by Scher et al 1997). 
1.4.2 Morphology 
Most superficial tumours appear papillary and may be multifocal and vary in size. Solid 
appearing tumours are more often invasive but this appearance can occasionally be 
misleading as some solid tumours actually have a compressed papillary structure on 
cross-section. Carcinoma-in-situ (CIS) is a flat, intraepithelial lesion, which may appear 
as a red, velvety area and is usually multifocal, but often occurring adjacent to discrete 
lesions. As CIS may also resemble normal bladder mucosa on cystoscopy, urine 
cytology is necessary to exclude this high grade entity, which fortunately, frequently 
sheds cells into the urine. 
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1.4.3 Grade 
Cancers vary in their behaviour in association with their gross and microscopic 
appearance. Hansemann proposed that tumour cells were derived from normal 
epithelium by a process of dedifferenciation in 1890 (Hansemann D., Ueber 
asymmetrische Zelltheilung in Epithelkrebsen und deren biologische Bedeutung. Arch f 
Path Anat 1890; CXIX: 299-326, as quoted by Busch et al 2001).28 30 years later, 
Broders developed this concept and published the first grading system, based on the 
proportion of differentiated to non-differentiated epithelial cells occurring in epithelioma 
(Broders AC. Epithelioma of the genitourinary organs. Ann Surg 1922; 75: 574-604, as 
quoted by Busch et al 2001). Since then, the grading system for urothelial carcinomas 
has been modified several times. The current WHO 1999 system is described and 
compared with the previous WHO 1973 system. 
Urothelial papilloma 
Papillary Urothelial Neoplasm of Low Malignant Potential 
This grade corresponds to the best differentiated tumours in the previous WHO 1973 
TCC grade 1. This grade represents a pattern that gives a predominant impression of 
order with very little variation of architectural and nuclear features. In such lesions there 
is generally no progression, no cancer mortality and a low frequency of recurrence 
compared with higher grades. 
Papillary Urothelial Carcinoma, Low Grade 
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This corresponds to the more atypical portion of WHO 1973 grade 1 TCC. This pattern 
yields an impression of predominant order but in which variation is easily recognized. 
The risk of progression and cancer death rate are low. 
Papillary Urothelial Carcinoma, High Grades 
WHO 1999 grade II 
This corresponds to WHO 1973 grade II. The overall pattern gives an impression of 
predominant disorder, but areas of orderly patterns can be distinguished. Nuclei are 
larger, with irregular forms and loss of polarity. Chromatin texture is coarse. Superficial 
cell differentiation is rare. Mitoses are numerous and irregularly distributed. The 
progression risk is approximately 20% and cancer death around 35%. (Malmstrom et al 
1987). 
WHO 1999 Grade III 
This corresponds to WHO 1973 grade III. The pattern gives an impression of total 
structural disorder. Mitoses are even more abundant, irregularly distributed and occur in 
clusters. The progression risk is 40% and cancer deaths 55%. (Epstein et al 1998).  
Exfoliative Urinary Cytology 
Cytology is most useful for high grade papillary lesions and CIS, which by definition is 
grade 3. The cytological features of urothelial carcinoma include increased nuclear size 
and irregularity in shape and chromatin texture and increased nuclear/cytoplasmic ratio. 
1.4.4 Stage 
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Jewett and Strong first demonstrated the prognostic significance between patients with 
bladder cancer that had no invasion, muscularis propria invasion or perivesical 
extension. (Jewett HJ and Strong GH, Infiltrating carcinoma of the bladder. Relation of 
depth penetration of the bladder wall to incidence of local extension and metastases. J 
Urol 1946; 55: 366-372, as quoted by Busch et al 2001). This system has undergone 
some refinement over the years. In the current 1997 AJCC/TNM staging system, staging 
of muscle-invasive disease has been further refined but the staging of superficial bladder 
cancer remains the same (Table 1). Superficial bladder cancer comprises Ta, T1 and CIS 
or combinations thereof. 
Table 1. 1997 AJCC/TNM Staging of Bladder Cancer 
 
Primary Tumour 
TX Primary tumour cannot be assessed 
Ta Noninvasive papillary carcinoma 
T1 Tumour invades into lamina propria 
T2 Tumour invades the muscularis propria (detrusor muscle) 
T2a Tumour invades inner half (superficial muscle) 
T2b Tumour invades outer half (deep muscle) 
T3 Tumour invades perivesical tissue 
T3a Microscopically 
T3b Macroscopically (extravesical mass) 
T4 Tumour invades any of the following: prostate, uterus, vagina, pelvic 
wall, abdominal wall 
T4a Tumour invades prostate, uterus, vagina 
T4b Tumour invades pelvic wall, abdominal wall 
 
1.4.5 Low risk and high risk tumours 
Superficial tumours have varying malignant potential, best predicted by a combination 
of characteristics and not grade or stage alone. They are best regarded as low risk and 
high risk. Low risk tumours such as a primary, solitary, stage Ta, grade 1, papillary 
tumour has a risk of progression of less than 2% (Heney 1992). High risk tumours share 
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3 or more of the following characteristics: CIS alone or concomitant with papillary or 
solid tumours, grade 3, T1, size greater than 3 cm, multifocality, previous recurrences, 
p53 positivity, failed previous intravesical therapy. Tumours with several of these risk 
factors may have a progression risk of more than 80%. 
1.5 Clinical management 
1.5.1 Presenting symptoms 
At first presentation, 70-80% of bladder tumours are superficial, 20-25% are muscle-
invasive and approximately 5% are metastatic. Haematuria is the presenting symptom in 
80-90% of cases. Some may present with a urinary tract infection, lower urinary tract 
symptoms (LUTS) from bladder wall irritation or a decreased functional capacity of the 
bladder. Some patients with ureteral obstruction may present with flank discomfort or 
pain or a mass. Rarely, pain from local progression or metastases may be the presenting 
symptom. 
1.5.2 Investigation 
The diagnosis is made by visualization of the collecting system by a combination of 
intravenous urography for the upper tracts (kidneys and ureters) and flexible cystoscopy 
(bladder and urethra). In my own experience, neither contrast-enhanced computer 
tomography nor ultrasonography has sufficient definition to exclude small lesions in the 
renal pelvis or urinary bladder conclusively. Urine cytology may be useful in the specific 
settings of the presence of abnormal bladder mucosa in the absence of gross tumour or a 
normal bladder in the presence of persistent isomorphic microhaematuria. In the latter 
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case, positive urinary cytology should prompt selective urine cytology from each ureter, 
retrograde pyelography and ureteroscopy with or without biopsy. 
1.6 Primary treatment and follow-up 
1.6.1 Transurethral resection 
The diagnosis is confirmed by transurethral resection (TUR) of the bladder tumour under 
general or regional anaesthesia. The tumour should be completely resected and the base 
of the resection sampled separately to determine the depth of tumour invasion as well as 
the completeness of the resection. TUR however, may leave microscopic foci behind, 
either in the tumour bed or elsewhere. Surgical mucosal trauma may also facilitate 
implantation of floating tumour cells, often at the dome of the bladder (because of 
thermal injury from rising hot water generated by cautery) and possibly also, at the site 
of resection (Sidransky et al 1992; Takahashi et al 1998). 
Directed biopsies of the peritumoral mucosa as well as any other abnormal areas of 
mucosa should be taken (May et al 2003). Bimanual examination of the bladder under 
anaesthesia, before and after tumour resection is helpful in clinical staging of muscle-
invasive tumours. 
1.6.2 Follow-up  
Virtually all patients with intermediate or high risk disease develop new tumours if 
followed up for 10 years or more (Cookson et al 1997).  On histopathological 
confirmation of low risk bladder cancer, the patient should be reassured and monitored 
by 6-monthly clinical review and cystoscopy. The guidelines of the Asia Pacific Uro-
oncology Society recommends that high risk patients undergo 3-monthly cystoscopy 
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with urine cytology for the first year and 6-monthly cystoscopy for the next 2 years and 
annually thereafter. Bladder biopsies are taken only when clinically indicated (Highshaw 
et al 2003).  A number of urinary tumour markers and detection kits have recently been 
developed and appear to be more sensitive than urine cytology for detecting low grade 
tumours but unfortunately have a lower specificity and may prompt unnecessary, 
intensive investigation. Their clinical role is currently being defined. 
1.7 Intravesical chemotherapy 
Intravesical administration of chemotherapeutic agents allows a high concentration of 
drug to come into direct contact with tumour or dysplastic urothelium, with little risk of 
systemic uptake. However, penetration into the bladder wall is only a few cells deep. 
Also, dilution of the therapeutic agent by the continuous production of urine occurs and 
may reduce the effectiveness of chemotherapy (Au et al 2001).  
The most commonly used chemotherapeutic agents are the anthracyclines, 
doxorubicin, epirubicin and valrubicin and the alkylators, thiotepa and mitomycin. All 
cause various degrees of cystitis and none has shown clear superiority over another. 
Compared with TUR alone, the 95% confidence intervals for relative reduction in 
recurrence rates for the 3 most commonly used intravesical agents are 12.4-25.2% for 
thiotepa, 10.7-23.4% for doxorubicin and 6.1-19.9% for mitomycin (Lamm et al 
1997). None of these agents has demonstrated a reduction in tumor progression rate 
(Lamm et al 1995; Nilsson et al 2001).  
Of note is that a single perioperative instillation of a chemotherapeutic drug, especially if 
administered within 24h of transurethral resection, is efficacious in reducing recurrence 
rates from 41% to 29% (p=0.015) (Kurth et al 1993).  
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Some patients with BCG-refractory disease, especially if low grade and low stage, have 
been treated with intravesical chemotherapy, with modest response rates. Recently, 
patients with tumour recurrence after BCG immunotherapy have also been successfully 
treated with intravesical gemcitabine (Dalbagni et al 2002). 
1.8 Bacillus Calmette-Guérin Immunotherapy 
Endocavitary therapy for bladder cancer combined with transurethral ablation is possibly 
the most successful example of immunotherapy for solid human malignancies. In the 
past two decades, there has been a steady growth of knowledge in this field, with 
concomitant improvement in prevention of tumour recurrence, progression and 
mortality. Rapid progress in intravesical therapies has made superficial bladder cancer a 
major area of development in oncology and has contributed to the fundamental 
understanding of processes in related fields, not least in tumour biology, immunology 
and immunotherapy. 
The success of BCG has stimulated the investigation of other biological response 
modifiers (BRM) such as keyhole limpet haemocyanin and bropirimine, new modalities 
such as laser and photodynamic therapy and new approaches such as chemo-
immunotherapy. This section however, will focus on BCG immunotherapy for 
superficial bladder cancer and provide a review of the most important aspects of this 
field. 
1.8.1 History of BCG as an antineoplastic agent 
BCG is an attenuated live strain of Mycobacterium tuberculosis var. bovis, developed by 
Albert Calmette and Camille Guérin in 1921, for vaccination against tuberculosis 
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(Morales 1994).1 BCG is now used worldwide for this purpose but its effectiveness in 
preventing tuberculosis appears variable. In 1929, Pearl reported a possible 
antineoplastic effect of tuberculosis infection. This information was submerged in the 
publicity surrounding the Lubeck disaster soon after and it was not until the development 
of animal tumour models in the 1950s, did any interest re-emerge. Mathe in 1959 first 
described the use of BCG as an adjuvant in the treatment of acute lymphoblastic 
leukemia. However, it was Coley who first successfully applied the concept of non-
specific immunotherapy in the late 19th century (Coley W.B. Treatment of malignant 
tumours by repeated inoculations of erysipelas, with a report of 10 cases. Med Rec 1883. 
43:60 as quoted by Morales, 1994.) This led to the transient use of autologous and 
allogenic tumour tissue in the early 20th century (Coca A.F., Dorrance G.M., Labredo 
M.G. Vaccination in cancer. A report of the results in vaccination therapy as applied in 
seventy-nine cases of human cancer. J Immunol & Expt Ther 1912. 13: 543 as quoted by 
Morales, 1994.)  
Subsequently, the success of BCG in the treatment of malignant melanomas was 
reported and spurred further research. Its success in melanoma was identified with 
development of a delayed type hypersensitivity reaction in skin. Subsequent studies by 
Coe and Feldman (1966) demonstrated that the urinary bladder was also capable of 
mounting a delayed type hypersensitivity reaction (Coe and Feldman 1966).  
Zbar, extending the work of Gross in the 1940s, defined the parameters for successful 
BCG immunotherapy viz. small tumour burden, intact immune system, direct contact 
with tumour and repeated treatments (Zbar et al 1972). 
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1.8.2 BCG and Bladder Cancer 
Thereafter, Morales demonstrated the effectiveness of non-specific active 
immunotherapy with intravesical BCG for 9 patients with superficial bladder cancer 
(Morales et al 1976). His empirical schedule, derived from an intravesical 
chemotherapeutic schedule, of 6 once-a-week intravesical instillations of BCG for a 2-
hour duration, has maintained its popularity. 
Two subsequent studies confirmed the effectiveness of BCG immunotherapy in reducing 
recurrence rates for bladder cancer (Camacho et al 1980; Lamm et al 1980). 
1.8.3 Efficacy of BCG Immunotherapy 
1.8.3.1 BCG Strains 
Calmette and Guérin passaged a virulent strain of M. tuberculosis var. bovis 208 times 
between 1908 and 1921, to obtain the avirulent strain. At that time, it was not possible, 
to preserve the live bacteria by freezing and so, this live vaccine was maintained by 
continuous passage, often in conditions that achieved the original attenuation, resulting 
in many phenotypically different daughter strains. Recently, the genomic differences of 
M. tuberculosis, M. bovis and the various BCG daughter strains were studied by 
comparative hybridization using DNA arrays. (Behr et al 1999). Up to 11 regions in M. 
tuberculosis were absent compared with M. bovis and an additional 38 open reading 
frames, representing 5 regions, were variably absent from the avirulent BCG daughter 
strains. One region was missing from all BCG strains and 4 from certain BCG strains 
only.  
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Nevertheless, there does not appear to be a significant difference in clinical efficacy 
amongst the various BCG strains (Table 2). (Lamm et al 1997). 
1.8.3.2 Efficacy in clinical trials 
Therapeutic v. prophylactic use 
Patients with CIS often have disease present when receiving immunotherapy, because 
this form of bladder cancer may be too diffuse for complete resection or may be 
invisible. The use of BCG immunotherapy is therefore considered therapeutic in this 
setting. Patients with papillary tumours in the absence of CIS, who undergo transurethral 
resection of these tumours, are believed not to have residual or incipient disease 
elsewhere in the bladder.  The use of BCG immunotherapy is therefore considered 
prophylactic in this group.  
However, in the latter group, re-biopsy of the original tumour base just one month after 
the original resection is often positive, nascent tumours may have been missed and 
tumour cell implantation before or at the time of resection may also have occurred, 
blurring the distinction between these two categories. (Mufti et al 1992; Takahashi et al 
1998. Chow et al 2000; Hafner et al 2001). 
Efficacy in CIS & papillary tumours 
Nevertheless, the efficacy of BCG immunotherapy is best appreciated in the context of 
patients who have disease present at the time of therapy as some patients in the 
prophylactic group would not have had an early recurrence even without therapy. For 
example, if 80% of a cohort is not at risk of early recurrence, then a short-term study in 
these subjects, would yield a maximum possible reduction in recurrence rates of 20%. 
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This explains in part the variation in response rates in the series presented below. In 
patients with CIS, Lamm’s review reported an average complete response rate of 72% 
from 41 series with a total of 1496 patients (Table 2, Lamm, 1997). 
Table 2. Comparison of BCG strains in the treatment of carcinoma in situ of the 
bladder (Lamm 1997). 








Connaught/8 450 357 79 70-92 
Tokyo/4 111 86 77 63-84 
Pasteur/7 230 171 74 40-80 
Tice/6 277 197 71 56-82 
Evans/6 180 117 65 53-88 
A Frappier/6 145 87 60 39-100 
S African/1 13 9 69 - 
Danish/1 42 28 67 - 
Romanian/1 33 21 64 - 
RIVM/1 15 9 60 - 
Total 1496 1082 72 39-100 
 
In patients with papillary tumours alone, in controlled studies comparing TUR alone to 
TUR and BCG, there is a reduction in relative recurrence from 20-65% (Table 3.)  
Table 3. Effect of intravesical BCG on recurrence in controlled studies (Lamm 
1997) 
 
 Control (TURBT) BCG  
Author Total number n Recurred n  (%) n Recurred n (%) 
Difference   
% recurred p-value 
Lamm 57 27 14 (52) 30 6 (20) 32 <0.001 
Herr 86 43 41 (95) 43 18 (42) 53 <0.001 
Herr 49 26 26 (100) 23 8 (35) 65 <0.001 
Pagano 133 63 52 (83) 70 18 (26) 57 <0.001 
Melekos 94 32 19 (59) 62 20 (32) 27 <0.02 
Krege 224 122 56 (46) 102 26 (26) 20 0.003 
Total 643 313 208 (67) 330 96 (29) 38  
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In 86 patients with a mix of superficial tumours (Ta, T1, CIS), who received 6 weekly 
instillations of standard dose BCG, there was also a decrease in tumour progression of 
28% v. 35% at 5-year follow-up and 37% v. 53% at 10-year follow-up compared with 
controls treated by TUR alone. (Cookson et al 1997). The difference in progression rate 
appears be lost at 15 years. However, it should be noted that many patients in the control 
arm were subsequently treated with BCG, possibly blurring the difference in 15-year 
outcomes. Likewise, there was an improvement in both disease-specific survival at 5 and 
10 years and of progression-free survival at 15 years also.  
A meta-analysis confirmed the observation that BCG reduces progression rate by 
approximately 25% when applied in an extended maintenance schedule beyond one year 
(Silvester et al 2002). 
Intravesical BCG does not appear to protect the upper urinary tract. In Cookson’s series 
(1997), 26% of all patients developed upper tract tumours by 15 years of follow-up. It is 
sobering that at 15 years, in this series of mixed superficial transitional cells carcinomas 
(Ta, T1, CIS), only 33% were alive with their bladders intact, 10% were alive but had 
undergone cystectomy, 23% had died from other causes and 34% had died of bladder 
cancer. 
1.8.3.3 Toxicity of BCG Immunotherapy 
Despite the proven efficacy of BCG immunotherapy, reports of major side effects 
including local and systemic infections and treatment-related deaths have restricted its 
use. (Kesten et al 1990; Lamm et al 1992a & 1992b; Rawls et al 1990). Nevertheless, 
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most patients tolerate intravesical BCG immunotherapy although some are unable to 
complete a schedule of treatments because of local or systemic toxicity. Irritative bladder 
symptoms are common but often self-limiting (Table 4). Some investigators have used 
izoniazid, aspirin, antihistamines and vitamin B6, to prevent or reduce side effects. 
However, many antibiotics are capable of killing BCG and may impair the 
immunological efficacy of BCG. Indeed, De Boer has reported that izoniazid severely 
impairs the immune response to intravesical BCG in guinea pigs (Van der Meijden et al 
1991; De Boer et al 1992) and may not actually decrease the side effects of BCG 
immunotherapy (Vegt et al 1997) but reports to the contrary exist (Hanna et al 1982; 
Chung et al 1973). 
Toxicity has restricted to use of BCG immunotherapy to patients with high-risk bladder 
cancer only, the rest being considered at too low a risk to warrant the possible adverse 
effects of BCG. Strategies to reduce toxicity have also included dose reduction of BCG 
(see below) and alteration of treatment schedules. 
Of note, is that South West Oncology Group studies suggest that there was little 
difference in toxicity between a course of 6 instillations and 6+3 instillations (Table 4). 
However, the number of instillations remain an important factor in the incidence and 
severity of toxicity as reported by Grossman and by Lamm (Lamm et al 2000).   
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Table 4. Incidence of Common Adverse Events Associated with any Instillation 
During Induction versus Maintenance Therapy 
 
 

























Dysuria 58% 26% 46% 
Frequency 40% 14% 34% 
Hematuria, microscopic  8% 9% 
Hematuria. gross } 39% 11% 19% 
Urinary tract infection 18% 1% 1% 
Fever 38% 17% 31% 
Chills 34% 14% 32% 




1.8.4 Mechanism of action of BCG 
1.8.4.1 Immune surveillance 
 There is a complex relationship, which varies between different tumour types 
and host environments. Nevertheless, the theory of immune surveillance postulates that 
the immune system plays a pivotal role in preventing the development of tumours. A T 
cell mediated response has been convincingly demonstrated in virally induced tumours 
but less so, for spontaneous or chemically induced tumours. (Allison et al 1967). A 
major argument in support of this theory is that renal transplant recipients, who receive 
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drugs like azathioprine and cyclosporin which suppress T lymphocytes to prevent graft 
rejection, are at increased risk of malignancy (Calne 1979; Kinlen 1982). 
1.8.4.2 Tumour cell antigens 
A prerequisite for immune surveillance is tumour cell recognition. It appears that few 
tumours express tumour specific antigens (Weiss 1977). When they do, it is often a 
virally encoded protein on the cell surface, which possibly occurs when viral DNA is 
integrated into host DNA in virally-induced tumours (Schreiber et al 1988). Many 
tumours however, express tumour associated antigens (TAA) (Ben-Aissa et al 1988). 
These molecules are usually seen during embryonal development and are not expressed 
in the adult but somehow are switched on in cancer cells e.g. alpha-fetoprotein (AFP) 
and carcinoembryonic antigen (CEA) (Fujioka et al 1986). 
1.8.4.3 Tumour cell detection and killing 
The classical cytotoxic T cell response is restricted to recognition of antigen in the 
context of MHC class I molecules. However, some class II restricted T cells may also 
exhibit cytotoxic activity (Lancki et al 1991). This cytotoxic activity may however, be 
inhibited by cytokines such as IL-4 and TGFβ (Kasid 1988). IL-4 inactivates IL-2 
induction of lymphokine-activated killer (LAK) activity from human lymphocytes. 
Kawakami et al 1989). 
Natural Killer (NK) cells (CD3-/CD4-/CD16+/CD56+) are large granular lymphocytes, 
which may contribute to immune surveillance. NK cell cytotoxicity is not MHC 
restricted and not dependent on prior immunization or immunogenicity of the tumour 
cell target (Lewis & McGee 1992). NK cells have been observed in small primary 
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tumours and in implanted tumours and are probably the precursors of LAK cells 
(Whiteside and Herberman 1992). NK cells have in vitro cytotoxicity against bladder 
cancer cells when co-cultured for several days. (Wang et al 1991). Also, BCG-activated 
NK cells (CD3-/CD8+/CD16dim/CD56+) in vitro have been implicated in perforin-
mediated tumour cell lysis (Brandau et al 2000). 
Macrophages have been identified in a variety of cancers including bladder cancer 
(Mantovani 1990; Prescott et al 1992). They demonstrate anti-tumour responses in vitro 
but require activation (Fidler et al 1976). One of the key activators is interferon γ (IFNγ) 
(originally called macrophage activating factor), a product of activated T cells. 
Macrophages probably synergise with T cells to effect natural immune surveillance 
against cancer. Macrophages kill tumour cells by releasing reactive oxygen 
intermediates and by producing other cytotoxic cytokines such as tumour necrosis factor 
α (TNF α) (Urban et al 1986). TNFα production by macrophages is induced by IFNγ 
and interleukin-1 (IL-1) (Philip and Epstein 1986). Interferon alpha (IFNα) and 
interferon beta (IFNβ) also increase the tumoricidal activity of macrophages in vivo 
(Gresser and Bourali 1970). and in vitro (Dean and Virelizier 1983). Macrophages, like 
NK cells, are able to exert antibody dependent cellular cytotoxicity (ADCC) via the Fc 
receptor. 
Polymorphonuclear lymphocytes (PMN) are also cytotoxic to certain tumour cells. This 
cytotoxicity is mediated by ADCC, the generation of free radicals and the release of 
toxic enzymes (Van Kessel and Verhoef 1990). 
It is probable that all of these processes contribute to immune surveillance. 
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Mechanisms of evasion by the tumour 
An important consideration in tumour surveillance is immunological escape by the 
tumour. Malignant cells in a tumour mass have a variety of phenotypes and it is 
conceivable that some at least would produce TAA but the majority of tumours are not 
immunogenic. It is probable that tumours suppress the immune response in their local 
environment by a variety of means including downregulation of MHC class molecules 
and secretion of prostaglandin E (Plesica et al 1975). 
 1.8.4.4 Cytokines 
Cytokines are large polypeptides and glycoproteins (Mr 5-50 kDa) which are produced 
by a wide variety of cell types for local communication between cells in an autocrine or 
paracrine fashion but not usually endocrine. Cytokines mediate their pleiotropic 
functions through specific cell surface receptors. Cytokines are produced by many 
unrelated cell types and exhibit a vast redundancy and ambiguity in their function. Also, 
the response to a cytokine is non-linear and several cytokines may interact on a single 
cell to produce an effect, which differs in type or magnitude from that produced by 
single cytokines alone. 
Interleukin-1 
IL-1 comprises 2 related polypeptides, (IL-1α and IL-1β). In PBMC, IL-1β appears to 
be the predominant form. Both forms are separately regulated. (Turner et al 1989). 
IL-1 has many biological effects. It induces IL-2 and IL-2 receptor (IL-2R) expression in 
T cells and in synergy with antigen, also causes T cell proliferation. (Alter and Bach 
1990; Dinarello 1998). Leukemic cells and renal cell carcinoma may also secrete IL-1. 
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Interleukin-2 
IL-2 is a 15.5 kDa glycoprotein, produced by activated T cells and some B cells. The 
biological effects of IL-2 are mediated by three forms of IL-2R, which have varying 
affinities for IL-2 (Gaffen et al 1997). 
On activation by antigen or mitogen, resting mature T cells produce IL-2 and IL-2R, 
which cause rapid clonal expansion of the effector cell population. IL-2 also stimulates B 
cells to produce IFNγ and IL-4. IL-2 also causes NK cell proliferation, with enhanced 
cytotoxicity and IFNγ production. Incubation of normal resting T cells with high 
concentrations of IL-2 results in the expansion of a population of lymphoid cells (LAK 
cells) that has potent cytolytic activity against fresh tumour target cells. These LAK and 
tumour-infiltrating lymphocytes (TIL) are under active investigation as adoptive 
immunotherapy. The clinical utility of IL-2 is limited by its toxicity at high 
concentrations, as it causes a profound capillary leak syndrome and hepatic dysfunction. 
Interleukin-6 
IL-6 is a glycoprotein with a mass ranging from 21 – 28 kDa. It is a multifunctional 
cytokine, produced by both lymphoid and non-lymphoid cells and regulates immune 
responses, acute-phase reactions and haematopoeisis (Hirano T 1998). 84 IL-6 in 
combination with IL-2 stimulates B cells to produce antibodies. IL-6 and IL-1 also 
synergistically stimulate the growth and differentiation of B cells. 
IL-6 is also involved in T cell activation, growth and differentiation. The effects of IL-6 
are also synergistic with IL-1 and TNF (Le et al 1998).123 IL-6 and IL-1 synergistically 
induce IL-2 and IL-2R expression in T cells. IL-6 also induces the differentiation of 
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cytotoxic T lymphocytes (CTL) in the presence of IL-2 (Takai et al 1988; Uyttenhove et 
al 1988). IL-6 also induces serine esterase and perforin, required for mediating target cell 
lysis in the granules of CTL (Takai et al 1988). 
Interferon gamma 
IFNγ is a glycosylated polypeptide (Mr 20 or 25kDa) with a high content of base 
residues, which makes it acid labile (Devos et al 1982; De Maeyer et al 1998). IFNγ has 
a single receptor. Soluble forms of this receptor, as well as those for TNFα and IL-6 
have been identified in normal urine and prevent the cytotoxic actions of IFNγ and 
TNFα in vitro. (Englemann et al 1989; Novick 1989). 
IFNγ is produced by T cells and NK cells. Based on the array of lymphokines secreted, 
two different subsets of mouse T helper (TH) cells have been described. TH1 cells 
secrete IL-2, IL-3, TNFβ and IFNγ whereas TH2 cells mainly produce IL-3, IL-4, IL-5 
and IL-10 but little or no IFNγ (Mosmann et al 1986). IFNγ preferentially inhibits the 
proliferation of TH2 but not TH1 cells, indicating that the presence of IFNγ will result in 
a preferential expansion of TH1 cells. TH1 cells drive the cellular immune response, 
which confers anti-tumour activity, in contrast to TH2 cells, which promote the humoral 
immune response. IFNγ also stimulates MHC class I and II and intercellular adhesion 
molecule-1 (ICAM-1) expression, activates macrophages and NK cells and is cytotoxic 




Tumour necrosis factor alpha 
TNFα is a 17kDa unglycosylated protein, which acts through a ubiquitous receptor, 
expressed on most cells except erythrocytes. 
TNFα has diverse functions, many of which are held in common with IL-1. It is 
responsible for cachexia. It can act as a co-stimulatory molecule for activated T cells and 
induces the TNF receptor on T cells, HLA class II, high affinity IL-2 receptors and IFNγ 
production. 
Interleukin-10 
IL-10 is a 18 kDa polypeptide with potent anti-inflammatory effects (de Waal Malefyt et 
al 1997). It inhibits cytokine synthesis in both T cells and NK cells by inhibiting 
activation of monocyte-macrophages and dendritic lineages. IL-10 strongly inhibits 
production of IL-1α, IL-1β, IL-6, IL-8, IL-10 itself, IL-12, GM-CSF, TNFα and several 
chemokines by activated macrophages (de Waal Malefyt et al 1991). IL-10 also inhibits 
granulocytes. In T cells, IL-10 may directly inhibit IL-2 and TNFα but not IL-4 and 
IFNγ. Activation of T cells in the presence of IL-10 can induce a long-lasting state of 
non-responsiveness or anergy, which cannot be reversed by IL-2 or by stimulation with 
anti-CD3 and anti-CD28 (Groux et al 1996). IL-10 also directly or indirectly inhibits 






IFNα is a Type I interferon and its production is possible in most cells of the body, in the 
event of a viral infection. IFNα can stimulate expression of MHC class I antigens on 
target cells, thereby increasing T cell cytotoxicity. Belardelli and Gresser reported that 
IFNα also enhances the specific cytotoxicity of sensitized lymphocytes against 
allogeneic tumour cells. Also, T suppressor cells, in delayed hypersensitivity responses, 
can be inhibited by interferon. The stimulatory effect of IFNα/β on the expression of 
delayed type hypersensitivity is due to the specific inhibition of either the generation or 
expansion of T suppressor cells. (Knop et al 1982; Knop et al 1987). NK cell activity 
can be increased by IFNα, within an optimal dose range, above which it is suppressed 
(Herberman et al 1982; Edwards et al 1985). 
Interferons are in clinical use for anti-tumour therapy. They may act indirectly by 
stimulating MHC antigen production, macrophage activation or T and NK cell activity. 
They may also have direct antiproliferative effects and may also downregulate oncogene 
expression e.g. c-myc and ras in malignant cell lines. They may also cause tumour cells 
to differentiate into non-malignant phenotypes. 
1.8.4.5 Cell adhesion molecules 
Adhesion of cells to each other and to matrix components is a vital function performed 
by cellular adhesion molecules. Three superfamilies of adhesion molecules exist; 
selectins, integrins (e.g. LFA-1 and VLA-4) and members of the immunoglobulin 
superfamily (e.g. ICAM-1, 2 and 3). The integrins are cell adhesion receptors expressed 
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on a wide variety of cells. The members of the immunoglobulin superfamily serve many 
functions within the immune system, including antigen presentation and recognition. 
LFA-1 and ICAM-1 
LFA-1 has 3 ligands, ICAM-1, 2 and 3 which are expressed on lymphocytes, monocytes 
and neutrophils. On activation, lymphocytes increase ICAM-1 expression markedly. 
ICAM-1 has the strongest affinity for LFA amongst the three ICAMS. ICAM-1 is 
expressed on endothelium and many epithelial cell types (Springer 1990). ICAM-1 
expression is strongly induced by several cytokines, including IL-1, IFNγ and TNFα and 
possibly aid cell localization in inflammation (Altmann et al 1989; Siu et al 1989). The 
role of ICAM-1 in tumour biology is unclear. ICAM-1 expression has been correlated 
with an increased propensity for tumour metastases. However, there is also evidence that 
metastases of human tumours are less common when MHC class I antigens and ICAM-1 
are highly expressed (Vanky et al 1990). 
1.9 Current problems in BCG immunotherapy for superficial bladder cancer 
The current problems with BCG immunotherapy pertain to efficacy and toxicity. 
In spite of its remarkable success, a significant proportion of patients does not respond 
initially or will relapse later. Also, toxicity albeit self-limiting in many instances, curtails 
its widespread use despite its proven efficacy. The original therapeutic dose and 
schedule were derived empirically, the latter by mimicking that for intravesical 
chemotherapy. The possibility exists that modification of the dose and treatment 




The original schedule of 6 once-a-week intravesical instillations of BCG was not inferior 
to schedules of 6 instillations followed by one dose of BCG 3-monthly or 1 dose of BCG 
monthly for up to 2 years (Hudson et al 1987; Badalament et al 1987). Tachibana also 
reported that a randomized trial using a monthly schedule of 12 or 18 BCG instillations 
demonstrated no advantage for additional monthly instillations (as quoted by O’Donnell 
MA 2001). Six instillations 6-monthly for 2 years have also showed no advantage. 
(Palou et al 1997). Also, Lamm has reported that a continuous 12-week course of BCG 
caused a reduction in immune stimulation in patients as measured by in vitro 
immunoproliferative assays (Lamm 1995). 
The first controlled trial to show a benefit with additional BCG was a study in patients 
with CIS who received 81 mg of Connaught strain BCG weekly either in a schedule of 6 
instillations or 6+3 instillations (the additional 3 instillations being given after a 6-week 
rest interval) of using. In this study, the “6+3” schedule had a significantly higher 82% 
response rate at 6 months compared with 70% in the 6-instillation arm (Lamm 1992). 
Several years after the start of our clinical trial, data from a trial designed to address the 
issue of additional (maintenance) BCG therapy, SWOG 8507, was published. In this 
study, patients received a “6+3” course of instillations followed by 3 weekly instillations 






1.9.2.1 BCG dose reduction – when more isn't better! 
Studies in murine transitional cell carcinoma have demonstrated a typical bell-shaped 
dose-response curve for BCG immunotherapy (Lamm et al 1982). However, with 
repeated administration, cumulative doses of BCG, which would, if given in one 
instillation, have suppressed the immune response, have resulted in heightened 
antitumour response. Clearly, optimal dose is dependent upon the schedule of 
administration. Blumenstein et al (unpublished data from Connaught Laboratories) 
found that variations in Connaught BCG between 0.83 -19.39 X 108 CFUs resulted in 
no detectable range in efficacy. In animal work on the protective effect of Connaught 
BCG to challenge from tuberculosis, Siebenmann and Barbara (1974) showed that a 
plateau of protective efficacy was reached at a certain dose; greater doses did not 
improve efficacy. A likely explanation of Blumenstein's finding is that the 
conventional dose of Connaught BCG is already on the plateau and could be lowered 
with no reduction in efficacy.   
Data from controlled dose reduction trials suggest that dose reduction lowers the 
toxicity of immunotherapy. Halving the 120mg standard dose of Armand Frappier 
strain BCG in a 6 weekly instillation schedule decreased toxicity from 33% to 12% but 
reduced response from 67% to 37% at a mean follow-up of 21 months in patients with 
Ta, T1 or CIS tumours (Morales 1992). In a 6 weekly (repeated if no response) plus 
monthly single maintenance instillation schedule for 2 years, halving the standard dose 
of 150 mg of Pasteur strain BCG reduced the incidence of cystitis from 57% to 32% 
and fever from 33% to 18% (Pagano et al 1995; Bassi et al 1999 and 2000). At a 
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median follow-up of 59 months, in 210 patients, the non-recurrence rates for the 
standard and low dose arms were 58% v. 56% for Ta (n.s.), 44% v. 53% for T1 (n.s.) 
and 30% v. 62% for CIS disease (p=0.006). Comparing conventional-dose Connaught 
BCG to one-third dose in an unblinded 500-patient study, Martinez-Pineiro found no 
difference in efficacy but significantly less toxicity with the reduced-dose treatment 
(Martinez-Pineiro 2003). This occurred in spite of using a 6 weekly induction schedule 
followed by 6 fortnightly instillations. Patients with multifocal tumours had a lower 
recurrence rate and progression rate with standard dose BCG but no statistically 
significant differences occurred for other high risk subgroups. 
Hence, reducing the dose of BCG in schedules, which use more than 6 instillations, 
maintains efficacy whilst reducing toxicity in these controlled but unblended trials. 
Possibly, the standard doses used for the various strains may be excessive and may 
contribute to toxicity.  
1.10 BCG and Interferon alpha 
There is sound immunological data to expect an enhanced antitumour response to a 
combination of BCG and interferon alpha. Although an initial study suggested little 
additive effect in the combination (Pryor et al 1995), our own studies as well as others, 
the combination had additive antiproliferative activity and cytotoxicity against a panel of 
human bladder cancer cell lines (Zhang et al 1997) and in enhancing cytokine 
production (Zhang et al 1999). These advantages translated to superior T cell activation 
and antitumour efficacy in a subcutaneous murine bladder cancer model (Gan et al 
1999). 
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In a phase I/IIa trial, using 6 instillations of half dose Pasteur strain BCG (Tice) with 
interferon alpha-2b at 10MU, 30MU, 60MU and 100MU, Stricker et al (1996) reported 
good responses in 9 of 12 patients and good safety. These data however, required 
validation in a larger phase II study.  
1.11 Aims of this study 
Part 1 
The aim of the first part of this study was to investigate the cellular immune response by 
analyzing urinary cytokines in patients with bladder cancer who receive intravesical 
BCG. This part is divided into 3 sections: validation of the methodology for urinary 
cytokine analysis, application of these findings to measure urinary cytokines in patients 
with bladder cancer and investigation of the biological role of some of these cytokines 
and adhesion molecules. 
Part 2 
The aim of the second part of this study was to develop a suitable protocol to address 
the issues of toxicity and efficacy of BCG immunotherapy, based on the findings of the 
first part of this study and to evaluate this in a clinical trial. The trial would have to be 
double-blinded to prevent biases in reporting toxicity (an inadequacy with the current 









 Material & Methods 
Section A. Development of a Protocol for the Assay of Cytokines in the Urine of 
BCG-treated Patients 
 
Urine samples from BCG treated patients 
Seven patients with carcinoma-in-situ of the bladder were treated with six consecutive 
weekly instillations of standard doses of Evans strain BCG (formerly Glaxo strain) 
administered through a urinary catheter. The solutions were retained for 2 hours after 
which the patient emptied his bladder completely. Fresh urine, which was subsequently 
passed, was used for these studies. The urine samples were collected within 4 hours 
and processed immediately in the laboratory. Urine cultures were obtained to exclude 
urinary infection. 
 
Processing of the urine 
The pH of the urine was measured (Table 5). Samples were then centrifuged at 2000 
rpm for 10 minutes. One half of this supernatant was then dialysed through a 10-kDa 
Visking tubing against a 20-times volume of phosphate-buffered saline (pH 7.3, 
0.045M containing 0.15M NaCl) at 4oC for 24 hours. The rest of the supernatant was 
stored non-dialysed at 4oC for 24 hours. The post-dialysis pH of the supernatants was 
measured to confirm the adequacy of the dialysis. 
 
Storage conditions 
The samples were aliquoted into 1 ml Cryovial tubes (Nunc). A batch of dialysed and 
non-dialysed supernatant controls was immediately stored at -70oC. The other samples 
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were then incubated at 22oC, 4oC and -20oC.  After each 24-hour period, appropriate 
vials were transferred to a -70oC freezer for storage prior to the ELISA assay. Prior to 
an assay, the required samples were thawed to room temperature.  
 
Table 5. Procedure for the processing of the urine 
 
Step Dialysed urine Non-dialysed urine 
1 Measure pH of sample. 
2 Centrifuge at 2000 rpm for 10 minutes. 
3 Dialyse through a 10 kDa 
Visking tubing against PBS for 
24 h at 4oC. 
Store for 24 hours at 4oC. 
4 Measure post-dialysis pH. 
5 Aliquot into sterile 1 ml Cryovials. 
6 Store batches of vials at 22oC, 4oC and -20oC. 
7 Retrieve samples at 24 h intervals and store at -70oC. 




IL-2, IL-6, IL-10, IFNγ and soluble ICAM-1 concentrations in the samples were 
determined using commercially available sandwich-ELISA assays as these are more 
convenient and have better reproducibility than biological assays (Anon. 1992).6 These 
kits may also measure inactivated cytokines, providing a closer approximation to total 
cytokine production, which for these studies may be more important than measuring 
biologically active cytokines alone (Fleischmann et al 1990).65 The kits used and their 
sources are listed in Table 6. IL-2 was measured with two different kits because of 
previously reported difficulties in assaying this cytokine in the urine. The Medgenix 
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oligoclonal kits are believed to detect both free and receptor-bound IL-2. The accuracy 
of the Medgenix IL-2 kit was reportedly not affected by soluble IL-2 receptor (CD25). 
To determine whether the levels of IL-2 measured had any correlation with soluble IL-
2 receptor (IL-2R), IL-2R was also assayed. For each cytokine, all the samples from a 
particular patient were assayed with the same kit to avoid interassay variation. Samples 
were assayed in duplicate using a standardized laboratory technique according to each 
manufacturer's instructions. 
 
Table 6. ELISA kits used 
 
Antibody(s)         Kit no.   Maunfacturer     Range 
Monoclonal anti-rIL2        RPN2142   Amersham           31.3-2000 pg/ml  
Oligoclonal antibodies to 
several IL-2 epitopes        40 124 00   Medgenix            0.1 - 30 IU/ml 
Monoclonal anti-rIL6        RPN2145   Amersham           31.3 - 300 pg/ml  
Oligoclonal antibodies to    40 123 00   Medgenix            0.03 - 30 IU/ml 
several IFNγ  epitopes 
Monoclonal anti-sICAM-1  BBE1/2    British         0.35-46 ng/ml  
        Biotechnology 
Monoclonal anti-IL2R           CK1020 T Cell Sciences   0.2 -  25 ng/ml 
Monoclonal anti-rIL-10       ASY-20     Biosource     5 -500 pg/ml 
        International 
 
Conversion formulae for IL-2: 
Amersham: [] ng/ml = [] x 1.55 + 0.02 ng/ml (NIBSC) 




Difference between dialysis before and after thawing 
To compare the effect of a freeze-thaw cycle on IL-2, IFNγ and sICAM-1 in dialysed 
and non-dialysed urine, urine samples were prepared at the same time, in the same 
manner as described above. These samples were incubated at 22oC, 4oC and -20oC for 
up to 144 hours. The samples were then transferred to a -70oC freezer. On thawing, the 
non-dialysed samples were immediately dialysed in the same manner as described 
above. On completion of dialysis, the samples were immediately assayed with the 
same kit as the pre-dialysed samples. 
 
Statistical analysis 
Statistical analysis was performed with Lotus 1-2-3 for Windows and GraphPad 
Instat2 software on a Toshiba T4400SX computer. 
 
Section B. Study of Changes in Urinary Cytokines and soluble Intercellular 
Adhesion Molecule-1 in Patients with Carcinoma-in-situ after bacillus Calmette 
Guérin Immunotherapy and their Functions  
 
1. For the studies in Part I Section B 
Patients  
The entry criteria for this study were extensive, poor prognosis carcinoma-in-situ of 
the bladder such as would otherwise warrant cystectomy and the absence of concurrent 
superficial or invasive tumours at the time of commencing BCG immunotherapy. The 
previous use of intravesical chemotherapy was not a contraindication for entry. For the 
purpose of this study, patients were evaluated at 3 months and 6 months after their first 
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course of intravesical BCG immunotherapy. Cure at these time points was defined as 
an absence of gross disease on cystoscopy, negative random bladder biopsies and 
negative urine cytology. 
 
BCG Immunotherapy 
Patients were treated with six consecutive weekly instillations of 1-5 X 109 colony-
forming units of Evans strain BCG (formerly Glaxo strain), diluted in 50 ml of normal 
saline and administered through a urinary catheter, which was then immediately 
removed. The solutions were retained if possible for 2 hours, during which time the 
patient was asked to adopt the recumbent position and to turn supine, prone and to the 
right and left lateral positions at 15 minute intervals to expose the entire mucosal 
surface of the bladder to the solution. The patient would then empty his bladder 
completely. All the urine, which was passed in the subsequent 12 hours, was then 
collected and assayed for cytokines. Urine was only collected for the first 12 hours as 
previous studies have shown that very little cytokine is produced after this period 45. A 
urine culture was taken each week to aid early detection of infection.  
 
Processing of the urine samples  
The urine samples were collected and processed within 12 hours.  The pH and the total 
volume of urine passed were measured. An aliquot of urine was then centrifuged at 
2000 rpm for 10 minutes. The supernatant was dialysed through a 10-kDa Visking 
tubing membrane against 2 litres of 0.2M phosphate buffered saline (pH 7.3) for 24 
hours, at 4oC. The post-dialysis pH of the urine was measured and the urine was 
aliquoted and stored at   -70oC. Prior to performing a cytokine sandwich-ELISA assay, 
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the specimens were allowed to thaw to room temperature. Excess urine was discarded 
and not re-frozen for use in other assays. 
 
Immunoenzymetric assays 
IL-2, IL-4, IL-6, TNFα, IFNγ and soluble ICAM-1 were measured in the urine by 
using human immunoenzymetric assays (ELISA). All the specimens from a particular 
patient were assayed with the same kit to avoid interassay variation. Samples were 
assayed in duplicate, using a standardized laboratory technique. The kits used for the 
sandwich-ELISA assays and their sources were as follows: IL-2 - Amersham 
International plc,  Aylesbury, Buckinghamshire (RPN 2142) and T Cell Sciences, 
Cambridge MA (CK1020), IL-4 - Medgenix Diagnostics, Brussels (RPN 2144), IL-6 - 
Amersham International plc (RPN 2145) and Genzyme Diagnostics, Cambridge MA 
(Predicta 1718-00), TNFα - Amersham International plc , IFNγ - Medgenix 
Diagnostics, Brussels (40 123 00) and soluble ICAM-1 -British Biotechnology 
Products Ltd, Abingdon UK (BBE 1). 
 
The concentration of each cytokine in a sample was then multiplied by the total 
volume of urine produced in the 12-hour period to obtain the total production for a 
particular instillation.  
 
Statistical analysis 
Statistical analysis was performed using Lotus 1-2-3 for Windows on an IBM-
compatible 386 computer. The non-parametric Mann Whitney U-test was performed 




All manipulations involving tissue culture were performed in a class II laminar flow 
safety cabinet (Envair Ltd, Rossendale, Lancashire, UK). Cells were cultured in 
complete medium (RPMI 1640 (Gibco, South Croyden, Surrey, UK) supplemented 
with 5% foetal calf serum (FCS) (Sera-Lab), sodium pyruvate (5mM) and L-glutamine 
(2mM) (both Gibco), unless otherwise stated. FCS was first heat inactivated by 
warming to 56°C for 1 hr prior to addition to RPMI medium. In experiments requiring 
serum free media, HB103 media was used (NEN). The cells were incubated and grown 
at 37°C in a humidified atmosphere of 5% CO2 in air. 
 
Bladder tumour cell lines 
Eight human transitional cell carcinoma (TCC) cell lines were used throughout these 
studies. These cells were the generous gift of Dr. J. Masters of the Institute of Urology, 
London, Dr. P. Perlmann, Stockholm, Sweden and Dr. J. Boyd, University of 
Edinburgh, UK. All cell lines were tested mycoplasma-free by the Public Health 
Laboratory Service, Porton Down, UK. The panel of cell lines represents various 
histopathological tumour grades. The cells have proved to be stable and their 
cytological appearances and growth characteristics have remained representative of the 
parent tumours. In order to minimize biological drift, cells were used for only a limited 
number of passages (n=10) before they were discarded and early passage number 
stocks re-cultured. 
 
For routine culture, cells were seeded at a density of 5x104ml-l and cultured in 
antibiotic- free complete medium in 25cm2 tissue culture flasks (Sterelin, Hounslow, 
Middlesex, UK). Cells were recovered for routine purposes by washing the monolayer 
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with phosphate buffered saline (PBS, Dulbecco A) and then trypsinizing using 1ml 
trypsin/EDTA solution (0.5 gl-l trypsin and 0.2 gl-l disodium EDTA (Sigma Chemical 
Co, Poole, Dorset, UK) for every 25cm2 of tissue culture plastic. Immediately 
following detachment of the cells, 10ml of complete medium was added to the cell 
suspension in order to neutralize the trypsin and saturate the EDTA. For some 
experiments, tumour monolayers were released without the aid of trypsin by using 
0.02% EDTA solution in PBS for 15 minutes. 
 
Multicellular Tumour Spheroid Agarose Suspension Techniques 
1% agarose plates were prepared with agarose (Difco Laboratories, Detroit, Michigan, 
USA) and phenol-free RPMI (Gibco RPMI 1640 medium without L-glutamine without 
phenol red. Cat. no. 041-02404 M). Store at 4oC in the dark).  The agarose was boiled 
in a 100 ml flask in the autoclave. Whilst the agarose was still hot, it was put in the 
hood in a hot water bath. 100 μl of agarose was placed in each well of a 96-well plate, 
sealed with tape and places in a 4oC fridge.  The plates kept for up to 1 month. When 
ready for spheroid culture, 4000 cells were placed in 200 μl of filtered 10% serum-
enriched RPMI (plus L-glutamate, phenol red, antibiotics etc.) in each well and placed 
in the incubator. Care was taken not to examine, move, jarr or slam the incubator door 
as any movement could cause disaggregation of the cells. After 3 days, the spheroids 
were ready for use.  The actual incubation time varied from cell line to cell line.  After 
the first 3 days, half the medium was replaced and then again, every two days. A 
microscope with a reticule was used to measure the spheroids in two diameters.  If 
spheroids necrosed in the centre, they could flatten. Therefore, for each experiment, 
about 10 spheroids were harvested, trypsinized and counted after adding trypan blue to 
identify dead cells. To harvest the spheroids, a glass micropipette was used to gently 
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suck them up. The spheroids were allowed to sink to the bottom of a small drop of 
medium, on a flat surface like a scalpel blade. Excess medium was dabbed off, taking 
care not to touch the spheroids, as this would destroy them. A drop of P.O.P. was 
placed on aluminium foil and the spheroids transferred to it. Then the foil was placed 
in either liquid nitrogen or dry ice and the mounting fluid allowed to solidify and 
opacify. It was then placed in a container and kept in a -20oC fridge. 
 
Isolation of peripheral blood mononuclear cells 
Peripheral blood was obtained from patients and normal healthy laboratory volunteers 
using a 19-gauge needle. Mononuclear cells were then isolated from the fresh, 
heparinized peripheral blood. Blood was diluted with an equal volume of PBS and 
layered onto one-third the volume of Ficoll-Isopaque (density=1.086 gcm3) and 
centrifuged for 30 minutes at 400xg. Following centrifugation, the upper phase was 
carefully removed and discarded. The interface was collected and subsequently washed 
three times in magnesium free Hanks balanced salt solution (HBSS) (Gibco). Adherent 
cells were removed by culture of the washed interface in 75cm2 tissue culture flasks 
for 1-2 hr. at 37°C. The non-adherent cells were recovered, counted and re-suspended 
at a density of 1x106ml-l in complete medium. Cells not required for immediate use 
were frozen in liquid nitrogen as described below. 
 
Urinary cytospins 
The urinary cytospins were prepared as follows: fresh voided urine was centrifuged at 
1500 rpm for 5 minutes. The supernatant was discarded and the pellet re-suspended in 
a few mls of serum-enriched RPMI. This was then spun at 700 rpm for 8 minutes 
against Poly-L-Lysine coated glass slides. The specimens were air-dried for 20 
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minutes and then fixed in acetone for a further 20 minutes and allowed to dry. The 
slides were then individually wrapped in aluminium foil and stored at -20oC. 
 
The slides were thawed for 20 minutes at room temperature before 
immunohistochemical staining.  The slides were washed in Tris-buffered saline 
(pH8.6) and the primary antibody, a mouse anti-ICAM-1 incubated with the specimen 
for 1 hour. The unbound primary antibody was then washed off with TBS and the 
secondary antibody, a biotinated rabbit anti-mouse antibody added and left for 30 
minutes. Streptavidin-linked alkaline phosphatase was then added and left for 20 
minutes, before washing off the excess. Finally, Fast Red substrate was added. The 
slides were counterstained with Meyer's haemulum and washed in alkaline water. 
 
Cell freezing, storage and thawing 
Cells obtained from peripheral blood and bladder cancer cell lines were stored in a 
liquid nitrogen filled vivo-stat. Washed cells were re-suspended at 2xl06ml-l in 90% 
foetal calf serum containing 10% dimethlysulphoxide (DMSO). Aliquots of 1ml were 
placed in freezing vials (Gibco) and these placed in polystyrene boxes. The boxes were 
transferred to a -70°C ultra low temperature freezer overnight prior to long term 
storage in liquid nitrogen until required (-196OC). 
 
Cells were recovered from long-term storage by rapid thawing to 37°C in a water bath. 
The 1ml aliquot was then washed twice with complete medium in order to remove any 
cell debris and DMSO. Using dye exclusion the viability of each vial was assessed 




The cytokines used during these studies were human recombinant E. coli-derived and 
of high purity, containing less than 2 endotoxin units per mg of cytokine protein, 
unless otherwise stated. The details of their specific activity, source and unit definition 
are as follows: 
Recombinant human IFNγ was purchased from Boehringer Mannheim (Lewes, East 
Sussex, UK) and contained 2.5xl07Umg-l protein. One unit was defined as the amount 
of IFNγ required to produce equivalent anti-viral activity to 1 unit of NIH reference 
standard Gg 23-901-530. 
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Table 7. Details of the antibodies used in these studies. 
Antigen Alternative name Source 
Dilution for flow 
cytometry 
CD3 - I 1:50 
CD4 - I 1:50 
CD8 - I 1:50 
CD11a LFA-1α II 1:50 
CD18 LFA-1β II 1:50 
CD54 ICAM-1 III 1:200 
ICAM-2 - III 1:100 
MHC class I - II 1:50 
MHC class II - IV 1:64 
IFNγ* - V - 
TNFα* - V - 
 
The table provides details of the monoclonal and polyclonal* antibodies used in the 
studies. The name of the antigen and alternative name (if any) is given. The sources of 
the antibodies are as follows: I - Scottish Antibody Production Unit (Law Hospital, 
Carluke, Lanarkshire, UK), II - Dako, III –Dr. T.A. Springer, IV – Dr I. Trowbridge, V –
Dr A. Meager (NIBSC). Also shown is the dilution of monoclonal antibody, which was 
used for flow cytometric staining procedures.  
 
Generation of LAK cells 
Non-adherent peripheral blood mononuclear cells (PBMC) were cultured at a density 
of 1x106ml-l in complete medium. LAK cells were generated by the addition of 
exogenous recombinant IL-2 (and other cytokines) at concentrations up to 1,000Uml-l. 
The mononuclear cells were incubated at 37°C in a humidified atmosphere of 5% CO2 
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in air for up to 6 days. After the incubation, the cells were washed twice in HBSS and 
resuspended at 4x106ml-l and assessed for cytolytic activity against labeled target 
cells. 
 
Source of Monoclonal Antibodies 
For details of antibody specificity and source see Table 3. For flow cytometry, 
monoclonal antibodies which were not directly conjugated to a fluorochrome were 
detected using a goat anti-mouse-IgG F(ab')2 fragment fluorescein isothiocyanate 
(FITC) conjugate (Sigma). 
 
Fluorescence Staining & Flow Cytometric Analysis 
Single and dual colour immunofluorescence were performed on cells stained indirectly 
or directly with monoclonal antibodies conjugated to either fluorescein isothiocyanate 
(FITC) or PE (phycoerythrin). For each analysis 1x105 cells were washed with 
washing buffer (PBS, 1% FCS, 0.01% sodium azide) and incubated at 4°C for 30 
minutes with optimal concentrations of primary monoclonal antibody. Following two 
washes by centrifugation, the binding of unconjugated monoclonal antibodies was 
detected using a sheep anti-mouse-FITC conjugate for a further 30 minutes at 4°C. 
Cells to be stained for two colour analysis were then blocked with a 10% (v/v) solution 
of normal mouse serum for 30 minutes and, after washing, incubated with a second 
monoclonal antibody conjugated to PE for a further 30 minutes. The cells were washed 
twice more and resuspended in 1% para-formaldehyde prior to analysis using a flow 
micro-fluorometer (Coulter, Hialeah, Florida, USA). Non-viable cells were gated out 
of the window and at least 10,000 events were accumulated by using logarithmic 
amplification of fluorescence intensity. 
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Induction of MHC class II and ICAM-l molecules 
Bladder cancer cells were cultured in 24-well, flat bottomed culture plates (Costar, 
Cambridge MA, USA) at 2x105/well at 37°C in a humidified atmosphere of 5% CO2 
in air. IFNγ was used at a concentration of 500Uml-l for 48 hr and 100Uml-1 for 24 hr 
in the case of MHC class II and ICAM-l induction respectively, unless otherwise 
stated. After incubation, cells were washed twice with ice cold PBS and harvested for 
analysis of expression of HLA class II and ICAM-1 molecules on their surface. 
 
Detection of soluble ICAM-l in tissue culture supernatants 
The presence of soluble ICAM-1 in tissue culture supernatants was determined using a 
sandwich ELISA test kit (T-cell Diagnostics, Cambridge MA, USA). Briefly, samples 
of cell-free tissue culture supernatant were incubated in the wells of a microtitre strip 
plate for 2 hours. Following washing, the presence of soluble ICAM-1 was detected 
using a second monoclonal antibody to ICAM-1, conjugated to HRP. 
 
Preparation of frozen sections of bladder tumour and multicellular spheroids 
Tumour biopsies and spheroids were collected and snap frozen in liquid nitrogen. Six 
μm frozen sections were cut at -25°C, air dried and fixed in fresh 100% acetone at 
room temperature for 2 hours. After further air-drying, they were wrapped in 
aluminium foil and stored desiccated at -20°C. 
 
Immunohistochemical method 
Frozen sections were recovered from -20°C storage and rehydrated with 0.2M tris 
buffered saline (TBS) pH 7.6 for 10 minutes. Following rehydration the slide around 
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the section was wiped dry and 100μ1 of an optimal dilution of primary monoclonal 
antibody was applied over the section. The slides were incubated at 20°C in a 
humidified atmosphere for 60 minutes following which they were carefully washed 
twice in TBS. Binding of the primary monoclonal antibody was detected using a 1:50 
dilution of rabbit anti-mouse immunoglobulin pre-conjugated to horse radish 
peroxidase (HRP) (Dakopatts, High Wycombe, Buckinghamshire, UK) for 30 minutes. 
This antibody was prepared in 10% normal human serum and pre-incubated for 30 
minutes at 20°C. After washing twice with TBS, the slides were flooded with substrate 
solution (diaminobenzidine DAB 3mg in 5ml DAB buffer, pH 7.6) (Sigma), which had 
been activated with 50 μ1 of 3% hydrogen peroxide solution in distilled water. After 
approximately 10 minutes, the substrate was removed by washing with TBS and the 
sections were lightly counterstained using Mayer's Haematoxylin (BDH Chemical Co., 
Thornliebank, Glasgow, UK) for 2 minutes. The counterstain was washed in alkaline 
tap water (pH 8.0) until all the excess stain had been removed. The sections were then 
progressively dehydrated by immersing in 30%, 70% and 100% ethanol solutions for 
1.5 minutes each prior to washing in sulphur-free xylene. The sections were then wet 
mounted using DPX mounting medium (BDH Chemical Co.).  
 
Sample preparation for electron micrography 
Multicellular spheroids were grown on agarose coated wells for 72 h following which 
LAK cells were plated on top and incubated for 24 h in a tissue culture incubator. After 
incubation the multicellular spheroids were washed with PBS (pH 7.2) and stored in 
glutaraldehyde. Fixed slides were freeze-dried and splutter coated with gold particles. 
Samples were scanned and photographed on a Phillips 505 electron microscope (Phillips 
Scientific, Cambridge, UK ). 
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Part II. A multicentre, double blind randomized clinical trial of intravesical 
bacillus Calmette-Guerin and interferon alpha-2b in the treatment of superficial 
bladder cancer 
Urinary cytokine studies 
The protocol described above was used. 
 
Patient and treatment details 
Please refer to Appendix 1.  
Please note that the Evans strain of BCG was replaced with the Connaught strain for 
this study because the Evans (Glaxo) strain had been withdrawn from the market. The 
Connaught strain was specifically chosen instead of the other available strains as this 
strain had been used in the SWOG study on the “6+3” regimen. 
Concern over the possible immunosuppressive effects of high doses of interferon alpha, 
led us to select the lowest effective dose of interferon alpha for this clinical study i.e. 


















Section A. Development of a protocol for the assay of cytokines in the urine of 
BCG-treated patients 
The aims of this study were to determine the optimal means of preserving urinary 
cytokine and soluble adhesion molecules in samples of patients' urine, to evaluate the 
effects of delay and temperature on samples and to determine the most economical 
means of storage. Also, as some of these cytokines and adhesion molecules were 
believed to be pH-labile, a comparison was made between a fresh urine sample which 
was acidic and one which was of neutral pH. 
 
IL-2 
IL-2 was stable at -20oC and 4oC in both dialysed and non-dialysed urine of neutral 
and acid pH (Table 8). It was also stable in non-dialysed urine at 22oC but was 
unstable in dialysed urine at that temperature. IL-2 was almost completely degraded 
within 72 hours in dialysed urine incubated at 22oC (Fig. 5).  The trend was similar for 
both Medgenix and Amersham assays. 
 
Comparison of Medgenix and Amersham IL-2 kits 
Using the Medgenix kit, in 3 patients, detectable IL-2 levels in non-dialysed samples, 
in both controls and samples stored at -20oC, were approximately similar to that of 
dialysed samples.  However, in 3 other patients, non-dialysed urine contained almost 
twice the level of IL-2 as dialysed samples. The yield from the Amersham kit was 
similar from both dialysed and non-dialysed samples. 
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However, for identical samples, the Medgenix assay was more "sensitive" and detected 
194% +/- 36% more IL-2 per sample of dialysed urine tested than the Amersham assay 
in 36 dialysed urine samples from 6 patients (Mann Whitney U test, p=0.0001). This 
difference was not solely due to the effect of soluble receptors, as no correlation 
existed between the difference and the amount of soluble IL-2R present  (Fig. 6). 
 
Table 8. Stability of cytokines in acidic & neutral urine at 4oC and -20oC 
Cytokine Kit  Dialysed   Non-dialysed 
/Patient               †Ctrl    ‡4oC    ‡-20oC  †Ctrl ‡4oC
 ‡-20oC 
    Mean Mean   Mean Mean 
    S.D. S.D.   S.D. S.D. 
IL-2 (pg/ml) 
/1  Amersham 195 162 147 159 100 142 
    18 13   10 13 
/1  Medgenix 309 279 320 262 324 266 
    10 11   31 43 
/2  Medgenix 436 498 507 493 413 432 
    51 45   21 80 
IL-6 (pg/ml) 
/1  Amersham 965 977 964 982 946 937 
    48 31   24 43 
INF  (iu/ml) 
/1  Medgenix 0.51 0.62 0.52 0.85 1.1 0.88 
    0.18 0.06   0.20 0.21 
/2  Medgenix 3.35 2.99 2.85 1.74 1.24 1.83 
    0.12 0.44   0.08 0.11 
sICAM-1 (ng/ml) 
/1  Br. Biotech. 18.7 17.8 17.4 11.4 9.9 11.3 
    1.0 0.7   0.6 0.3 
/2  Br. Biotech. 12.2 10.1 9.2 10.0 9.7 8.9 
    1.1 0.8   1.0 0.8 
 
† Controls - Time 0h. 
‡ Samples were incubated for 120h. 
Patient 1 - Fresh urine pH 6.26, dialysed urine pH 7.22. 
Patient 2 - Fresh urine pH 7.20; dialysed urine pH 7.22. 
Note that all the cytokines were stable at 4oC and -20oC but levels in non-dialysed 
urine were generally lower. 
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The quantity of IL-6 detected was independent of dialysis and pH (see Table 8). IL-6 
was stable in both dialysed and non-dialysed urine at 4oC and -20oC for at least 120 
hours. In non-dialysed urine, it was also stable at 22oC for at least 120 hours. However 




IL-10 was stable at 4oC in urine from BCG-treated patients but degraded rapidly over 
24 hours in both non-dialysed and dialysed urine at 22oC. 



























Soluble ICAM-1 was only unstable in dialysed urine incubated at 22oC and degraded 
within 72 hours. Unlike IL-2 and IL-6 however, there was significantly poorer 
detection of sICAM-1 in acidic non-dialysed urine compared with dialysed urine (see 
Table 8). The recovery of sICAM-1 in acidic non-dialysed urine was 61% +/- 5% 
(p<0.0003, paired t-test) of that in dialysed urine compared with 96% +/- 13% (p<0.22, 
paired t-test) in non-dialysed urine of neutral pH. Acidic thawed urine subjected to 
dialysis also showed a 2-fold increase in detectable sICAM-1 over non-dialysed levels, 
increasing from approximately 34% to 67% +/- 23%. 
 
INFγ  
In 4 of 5 patients with acidic urine, the recovery of IFNγ in non-dialysed urine 
(subjected to a freeze-thaw cycle) was very poor. However, IFNγ was stable in the 
dialysed urine of 4 patients at 4oC but degraded rapidly within 48 hours at 22oC (Fig. 
7a).  
 
In one patient with urine of neutral pH, there was significantly less IFNγ recovered in 
non-dialysed urine comparing controls and samples stored at 4oC and -20oC 
(p<0.0001, paired t-test). On average, there was 52% +/- 7% less detectable IFNγ in 
comparable non-dialysed samples despite the similar pH of non-dialysed (pH 7.20) and 
dialysed (pH 7.22) samples. 
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Fig. 7a. Stability of IFNγ in urine of pH 7.2 before dialysis 
 
In another patient with fresh voided urine of acid pH, an anomalous result was noted. 
Like the others, IFNγ was stable in both dialysed and non-dialysed urine stored at 4oC 
and -20oC. No significant change was noted in non-dialysed samples incubated at 
22oC. However, detectable IFNγ increased 5-fold in dialysed urine incubated at 22oC 
over 72 hours from 0.51 iu/ml in the control to 2.62 iu/ml (see Fig. 7b). Re-testing 
these urine samples yielded the same results. 
 

























Fig. 7b. Stability of IFNγ in acidic urine before dialysis 
 
Differences between dialysis before freezing and after thawing 
In a comparison of pre-freezing dialysis and post-thawing dialysis, it was generally 
noted that cytokine recovery was poorer when subjected to a freeze-thaw cycle in 
acidic urine. For example, freezing, thawing and then dialysis of acidic urine recovered 
only 69% +/- 4% of the total IL-2 recovered from similar urine which had been 
dialysed before being frozen (see Table 9). However, recovery of IL-2 after dialysis of 
thawed urine of neutral pH was no different from that of pre-dialysed urine. The same 
findings were noted for sICAM-1.  In the case of IFNγ, even freezing urine of neutral 
pH before dialysis decreased the yield to 70% +/- 20%. Interestingly in a patient with 
anomalous IFNγ data, there was an increased yield in IFNγ of 148% +/- 16% from 
freezing, thawing and then dialyzing acidic urine compared with pre-dialysed samples 
(p<0.02, paired t-test). This result varies from our previously reported experience and 
possibly indicates a confounder of some importance (see below). 


























Table 9. Comparison of pre-freezing and post-thawing dialysis on urinary 
cytokines 
 
  IL-2(pg/ml)  sICAM-1(ng/ml) IFN  (iu/ml) 
  P1 P2  P1 P2  P1  P2  
Controls 
Pre-dialysed 176 336  11.4 35.3  0.51  3.62 
Non-dialysed 149 -  3.9 40.7  0.85  2.29 
Post-dialysed 124 285  4.2 36.3  -  1.59 
 
4oC 
Pre-dialysed 229 321  11.2 35.4  0.75  3.84 
Post-dialysed 113 380  10.3 41.9  1.22  3.59 
 
-20oC 
Pre-dialysed 182 394  11.2 34.7  0.93  3.51 
Post-dialysed 81 295  8.0 37.6  1.22  2.58 
 
 
P1 - Patient 1, fresh urine pH 6.26, dialysed urine pH 7.22. P2 - Patient 2, fresh urine 
pH 7.20; dialysed urine pH 7.22. Note: There was poorer recovery of IL-2 and sICAM 
in acidic but not neutral urine, which had been frozen before dialysis. There was also 
poorer recovery of IFNγ in neutral urine in non-dialysed urine. There was greater 
recovery of IFNγ in acidic urine from P1, which had been frozen before dialysis but 




Section B.  
(I) Changes in Urinary Cytokines and soluble Intercellular Adhesion Molecule-1 
in Patients with Carcinoma-in-situ after bacillus Calmette-Guérin 
Immunotherapy. 
The study of the cytokines expressed in the response to BCG per se may increase our 
understanding of the local immunopotentiation of the bladder.  Secondly, the assay of 
urinary cytokines allows monitoring during BCG therapy without the attendant risks of 
bladder biopsies (primarily that of allowing direct entry of BCG organisms into the 
circulation). Hence, the aims of this study were to trace the changes in urinary 
secretion during BCG therapy of several TH1 and TH2 derived cytokines and cell 
adhesion molecules and to identify potential response markers.  
 
Clinical response  
Eleven patients with carcinoma-in-situ of the bladder were evaluable for assessment of 
response at 6 months post-BCG therapy. There were 2 females and 9 males, with a 
mean age of 72 years (range 57-86 years). At the time of receiving BCG therapy, none 
had any concurrent superficial tumours. Eight patients had complete remission of their 
disease at 3 and 6 months. Two patients did not respond and had carcinoma-in-situ still 
present at the 3-month evaluation. The third patient had recurrent CIS at the 6-month 
evaluation. Of these patients, one underwent a second full course of BCG therapy and 
two received cystectomy. All eleven patients became free of disease. 
Urinary cytokines 
There was considerable variation in the production of cytokines in individual patients. 
After the first instillation of BCG, IFNγ, IL-6 and IL-8 were detectable in most 
patients. TNFα was detected in one patient after the first instillation, in another after 
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the second and in the majority after the third instillation. Soluble ICAM-1 was 
detectable in four patients after the first instillation and in the majority after the second 
instillation. IL-2 was first detected in the fourth week in three patients and in all but 
four in the fifth week. The modal week of first detection of each cytokine is presented 
in Table 10. There was a general trend for all these cytokines and soluble ICAM-1 to 
increase with each instillation of BCG (Table 10). Comparing first and sixth week 
instillations, there were 40-fold and 205-fold rises in IFNγ and TNFα respectively. 
Similarly, for ICAM-1, IL-6 and IL-8, the rises were 16-fold, 6-fold and 7-fold 
respectively. IL-4 was not detectable throughout immunotherapy.  
 
Table 10. Modal  week of first detection of each cytokine (n=11) 
 




1 5 - 1 1 3 1 
 
It is interesting to note that even in this small group of patients, some differences 
appeared between responders and non-responders. The non-responders produced only 
half the IL-2 and two-fifths the soluble ICAM-1 but 50% more IL-6 than the 
responders. Comparing the total post-fifth and post-sixth instillation 12-hour 
production of responders and non-responders, these differences were significant for 
ICAM-1 and IL-6 (p<0.05 and p<0.02 respectively, Mann Whitney U test). Most 
responders produced moderate levels of all the inducible cytokines and soluble ICAM-
1 (Table 11). However, three responders did not have detectable IL-2 after their sixth 
instillation of BCG. All the responders produced IFNγ, IL-6 and soluble ICAM-1.  One 
non-responder did not produce any IL-2, IL-4, IL-6 or IL-8. The second non-responder 
produced soluble ICAM-1 and all the inducible cytokines except for IL-2. The third 
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non-responder produced moderate levels of all the inducible cytokines but produced no 
soluble ICAM-1. 
Table 11. Mean Total Post-instillation Cytokine Production (12 h) 
    
Instillation 1 2 3 4 5 6  
IFN  Mean 2398 879 2543 7744 5520 14040 
/IU Range 0-1667 0-1950 0-6862 255-46800 0-16660      0-46800 
IL-2  Mean 0 0 0 17 102  72 
/ng Range 0 0 0 0-148 0-666 0-447 
IL-4 /pg Mean 0 0 0 0 0 0 
IL-6 Mean 41 94 108 101 201 262 
/ng Range 0-159 2-494 1-305 28-411 61-653 87-449 
IL-8 Mean 374 1604 901 1737 2800 2626 
/ng Range 0-1056 0-6073 0-3645 0-6442 366-7728 0-8778 
TNF  Mean 2 16 17 36 115 142 
/ng Range 0-6 0-105 0-59 0-140 0-436 0-494 
ICAM-1 Mean 1 3 6 12 43 17 
/µg Range 0-8 0-11 0-17 0-43 0-291 0-57 
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Section B.  
(II) Interleukin-6 Studies 
 IL-6 is detectable in the urine of BCG treated patients. Therefore, the aims of this 
study were to investigate the constitutive expression of IL-6 by human bladder cancer 
of various grades, in vitro and in vivo, and their response to BCG organisms and IFNγ, 
a potent cytokine found in the urine of BCG-treated patients (Prescott et al 1990).156 
The studies on bladder tumor cell lines convincingly demonstrated that all but one of 
the cell lines constitutively expressed 1L-6 (Fig. 8) and that, in certain cases, this could 
be upregulated by BCG or IFN-γ. Interestingly, the grade 2 RT112 cell line did not 
produce any IL-6 while, among the IL-6 producing cell lines, RT4, a grade 1 cell line, 
produced the smallest quantity. The grade 3 cell lines produced 16.8 pg ml-1 to 6896 pg 
ml-1 per 106 cells in a 24-hour incubation. On stimulation with 100 IU of IFNγ for 24 
hours, there was variable induction in all 7 cell lines, representing a 10% to 600% 
increase in IL-6 secretion. The smallest percentage increases were seen in the cell lines 
that constitutively secreted large amounts of IL-6. However, the mean increase for the 
grade 3 cell lines was 204 (13 to 609) pg per 106 cells, but that for the grade 1 and 
grade 2 cell lines was only 15 (1 to 27) pg per 106 cells. Stimulation with BCG did not 
upregulate IL-6 production in the RT4, RT112, EJ18 and SD cell lines (Fig. 9). In 
contrast, the MGH cell line showed an increase from less than 6 pg ml-1 to 2237 pg ml-
1 per 106 cells, the 5637 cell line from less than 6 pg ml-1 to 64 pg ml-1 per 106 cells 
and the J82 line from 15,762 pg ml-1 to 47,056 pg ml-1 per 106 cells. In all these cases, 
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Fig. 8. Constitutive and IFNγ induced IL-6 secretion in vitro  
() – Tumour grade; grade 3 cell lines constitutively produced more IL-6. Confluent cell 
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Fig. 9. Constitutive and BCG induced IL-6 secretion in vitro 
() – Tumour grade; only grade 3 cell lines responded to BCG. Confluent cell cultures were 




Fig. 10 (A). IL-6 production in multicellular spheroids  
An RT4 human bladder cancer cell line was grown in agar plates to create a 3-
dimensional  multicellular spheroid, to compare with conventional cell cultures and to 





Fig. 10 (B) An SD human bladder cancer MCS shows increased IL-6 positivity 
after exposure to IFNγ 





Fig. 10(C). SD MCS showing increased IL-6 positivity after exposure to BCG. 
Note that similar to the flat surface culture experiments, the SD cell line produces more 
IL-6 after stimulation with IFNγ than with BCG. However, BCG is toxic to these cells, 
causing the spheroid to collapse. 
 
Interleukin-6 was detected in the urine of all 13 patients, and concentrations increased 
throughout the course of treatment. None of the patients had positive urine cultures 
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during BCG therapy. There was considerable individual variation in urinary IL-6 
production, with the total 12-hour postinstillation secretion ranging from 0 to 159 ng 
after the first instillation and 87 to 449 ng after the sixth instillation (Fig. 11). 
However, detectable levels of IL-6 increased in all patients, with a 5-fold increase in 
the mean total 12-hour postinstillation secretion from 54 ng after the first instillation to 
277 ng after the sixth instillation. The largest increases were noted in the patients 
showing no clinical response, with nonresponders producing 2.5 times more urinary 
IL-6 after the first instillation (p <0.05, Mann Whitney U test), 6 times more after the 
second (p <0.02, Mann Whitney U test) and 1.4 times more after the sixth instillation 







































The range of urinary IL-6 secretion after any particular instillation was, however, 
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large, resulting in a considerable overlap between nonresponders and responders. Thus, 
after the first instillation the range for responders was 0 to 131 ng and that for 
nonresponders 52 to 159 ng, and after the sixth instillation it was 87 to 426 ng and 245 
to 449 ng, respectively. 
Evidence for the constitutive expression of IL-6 in bladder tumors and its elevation after 
BCG therapy was obtained by immunocytological and immunohistochemical analysis of 
patient material. Of 10 patients in whom cytospin preparations were available, 5 showed 
mild positivity in specimens obtained in the first or second instillation and 7 after the 
final BCG instillation. Interestingly, in some patients there appeared to be a modest 
increase of 10 to 15% in the number and intensity of positive urothelial cells. Overall, 
however, positive staining was faint in both shed urothelial cells and shed neutrophils 
(Fig. 12). 
 
Fig. 12. Cytospin preparation from urine of patient after BCG therapy  
Cytospin preparation stained with monoclonal anti-IL-6. Note positive spiculation in 
shed urothelial cell, surrounded by smaller neutrophils. 
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Of 8 pre-BCG therapy bladder tumors, 3 grade 3 and 2 grade 2 tumors were positive 
for IL-6 (Fig. 13). The other 3 tumors, 1 grade 3 and 2 grade 2, were completely 
negative. Both post-BCG bladder tumors were grade 3 and positive for IL-6. One 
showed only mild staining, but the other showed moderately intense positive staining 
confined to the urothelium. The suburothelial tissues were negative (Fig. 14). Of the 
post-BCG random bladder biopsies taken 3 or 6 months after BCG therapy, all were 
negative for tumor. Three were completely negative for IL-6, and 4 showed mild to 
moderate positive staining in fewer than 10% of the urothelial cells. 
 
Fig. 13. Positive IL-6 staining in bladder tumour before BCG therapy 
Compare with negative control 6(below) and IL-6 positive post-BCG persistent 






Fig. 14. Above, IL-6 positive staining in a post-BCG persistent bladder tumour; 





















































Fig. 16. Diurnal pattern of urinary IL-10 secretion in normal subjects 
 
 
Urinary IL-10 was only intermittently secreted in normal controls, with a mean total 
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patients with TCC bladder. Urinary IL-10 was also increased in urinary tract infections 
(mean 189 +/- 5.4 ng/24h). In a comparison of spot samples, obtained at various times 
during the day, urinary IL-10 levels in patients with TCC bladder, before BCG 
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therapy, (n=38) and normal controls (n=35) were 123.3 +/- 54.5 ng and 0.97 +/- 0.39 
ng (Mean +/- S.E.; p=0.0001, Mann Whitney U test) respectively and their urinary IL-
6 levels were 35.8 +/- 10.8 ng and 1.53 +/- 1.49 (Mean +/- S.E.; p=0.037, Mann 






















Fig. 21. Ratio of Urinary IL-10 to IL-6 in patients with bladder cancer, urinary 
tract infection and normal subjects 
 
Urinary IL-6 and IL-10 appeared to share an inverse relationship. The mean IL-10/IL-6 
ratio in normal controls, urinary tract infection and TCC bladder were 0.7, 1.9 and 3.6 
respectively. Nevertheless, there is considerable overlap between the 3 groups, making 








Fig. 22. IL-6 positive bladder tumour biopsy 
A bladder tumour, before BCG therapy, shows positive staining for IL-6. A series of 
TCC obtained from patients with bladder cancer showed similar positivity for IL-6. A 





Fig. 23. IL-10 positive bladder tumour biopsy 
The same section of bladder tumour also showed positive staining for IL-10. The 
distribution of positive cells was remarkably similar, suggesting that the same cells 
were producing both cytokines. However, there is some IL-10 positivity in the 








Fig. 24. IL-10 positivity in a biopsy from pre-BCG treated TCC bladder 
Another bladder tumour biopsy showing marked positive staining for IL-10 in the 





Fig. 25. A high power magification showing an IL-10 positive bladder tumour 
biopsy 
Note the strong positivity in the cytoplasm of this poorly differenciated transitional cell 
carcinoma. A urine culture were negative in this patient.  
 
 
These experiments confirm that one of the sources of elevated urinary IL-10 are the 
bladder tumour cells themselves. They may do so in response to endogenous IL-6 
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production. Anti-IL-6 applied to human TCC cell lines in vitro decreases endogenous 
IL-10 production (data not shown). 
 
Section B.  
(III) ICAM-1 Studies 
None of the 18 patients' tumour cells was initially positive to ICAM-1 staining. 
However, with each week of BCG therapy, an increase in positive staining of tumour 
cells was noted with the maximum occurring after the 6th instillation of BCG (Fig. 
26). LFA-1 activated lymphocytes were noted in close apposition to many of these 
tumour cells (Fig. 27). The positive staining remained for up to six months post-
therapy. However, two patients showed weak staining. One of the two was completely 
negative at the 3-month assessment and had no regression of his carcinoma-in-situ. He 
was treated with cysto-urethrectomy. The other patient remained disease-free at 6 
months follow-up and also had moderately high levels of sICAM-1 in his urine. The 





Fig. 26. Urinary cytospins after BCG Immunotherapy 
(A) Urothelial cells often appear in close apposition to polymorphonuclear 
lymphocytes (H & E, control) after BCG immunotherapy. (B) Stong positive staining 






Fig. 27. Post-BCG therapy urinary cytospin showing LFA-1 positive leucocytes 
 





Fig. 29. A series of urinary cytospins from post-BCG therapy patients showing 







































Fig. 30. HLA-DR expression in RT4 (1), RT112 (2) and SD (3) multicellular 
spheroids  
3-day old multicellular spheroids were stimulated with IFNγ 1000 IU/ml for 72h. 
Experiments were performed independently twice, in triplicate. () – grade of parent 































Fig. 31. ICAM-1 expression in RT4 (1), RT112 (2) and SD (3) multicellular 
spheroids 
3-day old multicellular spheroids were stimulated with IFNγ 100 IU/ml for 24h. 
Experiments were performed independently twice, in triplicate. () – grade of parent 
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Fig. 32. ICAM-1 expression in RT4 multicellular spheroids  
3-day old multicellular spheroids were stimulated with IFNγ 100 IU/ml for 24h and 
harvested on day 4, 5,6 and 7. Experiments were performed independently twice, in 
triplicate. () – grade of parent tumour.  * p= 0.01 This data suggests that a single 
exposure to IFNγ causes a progressive increase in ICAM-1 expression in the cell line.  
 
 
Scanning electron micrographs (SEM) graphically demonstrate the direct toxicity of 
IFNγ 100 IU/ml for 24h on 3-day old RT112 multicellular spheroids (Figs.33A-D, G, 
H). As cells undergo apoptosis, gaps appear on the surface of the spheroid in contrast 
to the smooth surface of the control spheroid. 
However, when 3-day old RT112 multicellular spheroids are pre-treated with IFNγ 
100 IU/ml for 24h and then exposed to LAK cells, the spheroids become densely 
coated with a carpet of small, round LAK cells (Fig. 33E), which then proceed to 
rapidly destroy the tumour cells (Figs. 33F). At higher magnification, the typical hairy 
appearance of activated lymphocytes is apparent, in close proximity to the larger 

















Fig. 33 (C). RT112 multicellular spheroid, control (Magnification 625X) 
 
 





Fig. 33(E). RT112  multicellular spheroid exposed to IFNγ 100 IU & LAK cells for 
24h ((Magnification 625X) 
 
 




Fig. 33 (G). RT112 multicellular spheroid, control (Magnification 2500X) 
 
 










Fig. 33(I). SD MCS exposed to IFNγ and LAK cells (Magnification 2500X) 
The small hairy cells are activated lymphocytes (LAK cells) and are closely adherent 






Part II. A multicentre, double blind randomized clinical trial of intravesical bacillus 
Calmette-Guérin and interferon alpha-2b in the treatment of superficial bladder 
cancer 
 
Section A. A comparison of urinary cytokines in low and standard dose BCG 
therapy and low dose BCG with IFNα in a “6+3” schedule for bladder cancer 
For all the groups (n=42), urinary cytokines were measured before and for 12 hours after 
BCG instillation.  Except for IL-6 and IL-10, none of the other cytokines could be 
detected in significant quantities in most of the pre-treatment samples. Following BCG 
treatment, an increase in IL-2, IL-6, IL-10, TNFα, and IFNγ  (Figs. 34-38) was observed 






















Fig. 34. Post-BCG total 12-h urinary IL-2 in patients on a 6+3 schedule of 
instillations  























Fig. 35. Post-BCG total 12-h urinary IL-6 in patients on a 6+3 schedule of 
instillations 
A – Standard dose BCG; B – Low dose BCG; C – IFNα & BCG 
 
Cytokine production was generally higher in the combination therapy (BCG and IFNα) 
arm compared with the rest. However, a statistically significant difference was only 
consistently observed for IFNγ. A general increase in the amount of cytokines secreted 





















Fig. 36. Post-BCG total 12-h urinary IL-10 in patients on a 6+3 schedule of 






















Fig. 37. Post-BCG total 12-h urinary TNFα in patients on a 6+3 schedule of 

























Low dose BCG and Intron A
 
Fig. 38. Post-BCG total 12-h urinary IFNγ in patients on a 6+3 schedule of 
instillations 
The urinary cytokine analysis revealed that patients receiving BCG and IFNα produced 
much higher levels of the urinary interferon gamma than those on BCG alone. IFNγ 
production is associated with a positive anti-tumor response of BCG and may explain the 
superiority of combined therapy to BCG alone 
 
 
Comparing the differences between the first instillations of the induction and 
booster courses (1st and 7th instillations) 
There were significant differences in urinary cytokine production between the first 
instillations of the induction and the booster courses for both groups, with peak 
cytokine production observed in the booster course. IL-2, TNF-α and IFN-γ were 
significantly higher in the 7th instillation for patients in all 3 treatment arms. No 
significant difference was observed in cytokine production between the first and the 
seventh instillation for IL-6 and IL-10.  
Urinary cytokines during maintenance therapy 
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Cytokine production during maintenance instillations is much higher than during the 
induction course (first 6 instillations) (Fig. 39). During the first booster course (7th to 
9th instillations), denoted M1 to M3 in Fig. 39, there is a peak on the first of the booster 
instillations and then a decrease. This pattern is repeated for the next booster course 


























Fig. 39. Urinary cytokine profile during maintenance therapy 
Comparing the cytokine profile of responders and non-responders 
The data was pooled to study the cytokine profile of responders (n= 34) and non-
responders (n=9). Overall responders produced significantly higher amounts at the 
booster instillations for all measured cytokines except IL-10 when compared with non-
responders (Figs. 39-41).  It appears that urinary IL-2 or IFNγ during the booster (7th to 


























Fig. 41. Scattergram of urinary IL-2 in responders and non-responders 
Red – responder; green –nonresponder 
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Fig. 42. Scattergram of urinary IFNγ in BCG responders and non-responders  
Red – responder; green –nonresponder 
 
 
Fig. 43. Scattergram of urinary IL-10 in BCG responders and nonresponders 
Note that there appears to be little difference in the Th2 cytokine, IL-10 between the 2 
groups unlike the Th1 cytokines.  Red – responder; green –non-responder 
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Section B. Toxicity Analysis 
This study was double blinded and patients were asked to record their symptoms weekly, 
using a linear analogue scale for recoding of intensity of some symptoms. Overall, the 
treatment was well tolerated. A few patients who had persistence of symptoms at the 
scheduled time for their next instillation, had their treatment postponed a week. There 
were only 2 withdrawals from the study before the 3rd instillation because of adverse 
events. However, none of the patients on maintenance therapy completed 3 years of 
therapy. This was not due to toxicity but to patient or physician reluctance to continue 
with therapy after a prolonged disease-free interval.  
Serious adverse events 
Hematuria (prolonged)* 3 
BCG cystitis (> 30 days) 8 
Urinary tract infection 4 
Polyarthritis/arthralgia 7 
Conjunctivitis, uveitis etc 3 
TB epididymo-orchitis 1 
TB nodules on glans penis 1 
Skin rashes 3 
Urinary incontinence 5 
LUTS 1 
 
Table 12. Severe adverse events occurring in this study 
* Following traumatic catheterization in a patient with low platelet count 






Also, 6 of the first 48 patients had BCG cystitis, defined as experiencing symptoms of 
bladder inflammation for more than 1 month after completing BCG therapy. An 
investigation into these patients, who arose equally amongst the arms, revealed that all 
had some post-void residual urine of 30-100 ml. For the next 48 patients, a uroflow test 
and a residual urine volume assessment by ultrasonography were performed. In this 
group, patients with an identified post-void residual after 2 attempts at voiding were 
catheterized at the end of their BCG treatment in order to completely empty their 
bladders. None of the next 48 patients developed BCG cystitis (p<0.001, Mann 
Whitney test). 
Previous exposure to tuberculosis or BCG vaccination 
Toxicity symptom p value, Mann Whitney test 
Haematuria 0.002 




Influence on work & activities <0.001 
 
Table 13. Patients with prior exposure to tuberculosis had a higher incidence of 
toxicity 
Two patients had previous tuberculosis and 10 others had received BCG vaccination. 
Comparison of toxicities between the treatment arms 
There was a statistically significant decrease in both local and systemic therapy in both 
the low dose BCG arms compared with standard dose BCG during the first 6 
instillations (induction course) (Table 14). The addition of IFNα did not increase 
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toxicity. However, during instillations 7 – 9, the incidence and severity of toxic side 
effects were similar, as expected from a secondary immune response. 
 103 




(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
(1-6) vs (7-9) 
               
Local (Dysuria, burning sensation, frequency, urgency, haematuria, nocturia, incontinence) 
Standard dose BCG 100.0 59.0 89.8 88.1 91.7 89.8 83.9 100.0  91.5 91.5 87.2 70.3 P<0.001 
LD BCG 92.9 50.0 85.7 78.6 74.1 76.9 65.4 92.9  95.2 80.0 78.9 62.5 P<0.01 
LD BCG+Interferon 95.2 52.4 75.6 70.0 72.5 75.0 71.8 88.1  87.9 91.2 87.1 76.7 ns 
     P<0.05   P<0.05       
               
Overall 96.9 55.0 84.4 80.3 81.9 82.4 76.0 94.7  91.1 89.1 85.4 70.5 P<0.001 
               
Systemic (Fever, malaise, lassitude, difficulties with work and activities) 
Standard dose BCG 96.7 31.1 60.0 67.8 72.9 69.5 67.3 96.7  77.1 83.3 82.9 71.9 P<0.001 
LD BCG 71.4 28.6 35.7 53.6 55.6 42.3 38.5 71.4  71.4 65.0 57.9 50.0 ns 
LD BCG+Interferon 85.7 35.7 36.6 47.5 57.5 62.5 57.9 73.8  68.6 74.3 78.1 67.4 ns 
 P<0.01  P<0.05   P=0.06 P=0.05 P=0.001       
               
Overall 87.8 32.1 47.3 58.3 64.3 61.6 58.0 84.0  73.1 76.7 76.1 65.5 P<0.001 
               
Any local or systemic               
Standard dose BCG 100.0 67.2 91.5 91.5 95.0 93.2 89.1 100.0  93.8 95.8 92.7 76.6 P<0.001 
LD BCG 92.9 57.1 85.7 82.1 81.5 76.9 69.2 92.9  95.2 80.0 84.2 62.5 P<0.01 
LD BCG+Interferon 97.6 64.3 80.5 77.5 77.5 80.0 76.9 90.5  88.2 91.4 93.8 79.1 ns 
     P<0.05   P=0.06       
               
Overall 97.7 64.1 86.7 85.0 86.6 85.6 80.8 95.4  92.2 91.3 91.3 74.1 P<0.001 
               
Both local & systemic               
Standard dose BCG 95.1 23.0 58.3 64.4 69.5 66.1 62.5 93.4  74.5 78.7 76.9 65.6 P<0.001 
LD BCG 67.9 21.4 35.7 50.0 48.1 42.3 34.6 67.9  71.4 65.0 52.6 50.0 ns 
LD BCG+Interferon 83.3 23.8 31.7 40.0 52.5 57.5 52.6 66.7  67.6 73.5 71.0 65.1 ns 
 P<0.01   P=0.05   P=0.06 P=0.001       
               
Overall 85.5 22.9 45.0 53.5 59.5 58.4 53.3 79.4  71.6 74.3 69.7 61.9 P<0.01 
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(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
(1-6) vs (7-9) 
               
Standard dose BCG 78.7 8.2 41.7 30.5 42.4 39.0 35.2 68.9  54.2 51.1 56.1 50.0 P<0.05 
LD BCG 50.0 10.7 21.4 14.3 22.2 19.2 15.4 35.7  38.1 40.0 36.8 31.3 ns 
LD BCG+Interferon 61.9 0 9.8 15.0 22.5 25.0 15.8 31.0  40.0 60.0 50.0 53.5 P<0.05 
 P<0.05  P<0.01  P=0.06  P=0.05 P<0.001       
               
Overall 67.2 6.1 27.1 22.0 31.7 30.4 24.6 49.6  46.2 52.0 50.0 46.8 ns 
               
 
Note: The overall percentage is calculated on the ‘incident’ event i.e. a one patient is only counted once despite multiple occurrences of the event. 
 
‘% yes (Of all patients)’ 
Treatment 1 2 3 4 5 6  7 8 9 
           
Within 24 hrs           
Standard dose BCG 6.7 36.7 25.4 40.7 32.8 35.2  43.5 32.6 35.9 
LD BCG 10.7 21.4 11.1 19.2 19.2 12.0  38.1 30.0 36.8 
LD BCG+Interferon 0 9.8 15.0 20.0 25.0 15.8  30.3 44.1 38.7 
           
Overall 5.4 24.8 19.0 29.6 27.4 23.9  38.0 36.0 37.1 
           
> 24 hrs           
Standard dose BCG 0 5.0 5.1 1.7 5.2 0  8.7 17.4 17.9 
LD BCG 0 0 0 0 0 0  0 10.0 0 
LD BCG+Interferon 0 0 0 2.5 0 0  6.1 14.7 9.7 
           
Overall 0 2.3 2.4 1.6 2.4 0  6.0 15.0 11.2 
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(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
(1-6) vs (7-9) 
               
Standard dose BCG 98.4 31.1 56.7 61.7 60.0 67.8 64.3 91.8  74.5 78.7 74.4 65.6 P<0.001 
LD BCG 92.9 28.6 64.3 42.9 48.1 53.8 46.2 82.1  81.0 70.0 78.9 62.5 ns 
LD BCG+Interferon 81.0 26.2 46.3 47.5 52.5 50.0 51.3 66.7  64.7 67.6 67.7 62.8 ns 
 P<0.01       P<0.01       
               
Overall 91.6 29.0 55.0 53.1 55.1 59.2 56.2 81.7  72.5 73.3 73.0 64.0 P=0.001 
               
 
Intensity ( 1 – 10) - (Score 0=absent are excluded, 1= bearable and 10=unbearable) 
1 2 3 4 5 6 Initial(1-6) TREATMENT 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
               
Standard dose BCG 2.89 1.76 4.03 2.15 4.14 2.35 3.81 2.20 4.05 2.10 3.81 1.90 3.87 2.11 
LD BCG 3.00 1.07 3.89 2.17 4.17 1.99 4.54 1.94 4.07 1.94 3.50 2.11 3.92 1.95 
LD BCG+Interferon 3.91 1.81 3.89 2.51 3.79 1.90 3.57 1.66 4.20 1.70 4.10 1.68 3.91 1.87 
 -  -  -  -  -  -  -  
               
Overall 3.21 1.68 3.96 2.23 4.04 2.15 3.87 2.01 4.09 1.95 3.84 1.86 3.89 2.01 
               
 7 8 9 Booster (7-9) Overall (1 to 9) (1-6) vs (7-9)   
 Mean SD Mean SD Mean SD Mean SD Mean SD     
               
Standard dose BCG 4.57 2.57 4.43 2.46 4.62 2.41 4.53 2.46 4.09 2.25 P<0.05   
LD BCG 4.06 1.82 4.00 1.75 3.80 1.52 3.96 1.67 3.93 1.85 ns   
LD BCG+Interferon 5.09 2.76 5.78 2.92 4.95 2.62 5.29 2.76 4.43 2.33 P<0.001   
 -  P=0.06  -  P<0.05  -      
Overall 4.61 2.48 4.77 2.57 4.54 2.32 4.64 2.45 4.16 2.21 P<0.001   







(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
              
Standard dose BCG 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00  5.00 4.00 5.00 4.00 
LD BCG 4.00 3.00 3.50 4.00 4.00 3.50 3.00 4.00  4.00 4.00 4.00 4.00 
LD BCG+Interferon 4.00 3.00 3.00 3.00 3.00 3.50 4.00 3.00  5.00 6.00 5.00 5.00 
KW test - - - - - - - -  - - - - 
              
Overall 4.00 3.00 3.00 3.00 3.00 3.00 4.00 3.00  4.50 4.00 4.00 4.00 
              
 
 
Of all patients 
 
% yes 
Treatment 1 2 3 4 5 6  7 8 9 
           
Within 24 hrs           
Standard dose BCG 13.1 40.7 42.4 46.7 50.0 50.0  47.8 46.8 38.5 
LD BCG 14.8 55.6 35.7 40.7 44.0 36.0  66.7 40.0 52.6 
LD BCG+Interferon 16.7 36.6 37.5 40.0 32.5 30.8  30.3 35.3 35.5 
           
Overall 14.6 42.5 39.4 43.3 43.1 40.8  46.0 41.6 40.4 
           
> 24 hrs           
Standard dose BCG 18.0 15.3 18.6 13.3 17.2 14.3  26.1 31.9 35.9 
LD BCG 11.1 7.4 7.1 7.4 8.0 8.0  14.3 30.0 26.3 
LD BCG+Interferon 9.5 9.8 10.0 12.5 17.5 20.5  33.3 32.4 32.3 
           
Overall 13.8 11.8 13.4 11.8 15.4 15.0  26.0 31.7 32.6 
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(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
(1-6) vs (7-9) 
               
Standard dose BCG 68.9 18.0 32.8 32.2 27.6 29.3 25.0 55.7  38.3 42.6 39.5 35.9 P<0.05 
LD BCG 67.9 39.3 57.1 42.9 44.4 42.3 50.0 67.9  38.1 40.0 42.1 40.6 P<0.05 
LD BCG+Interferon 64.3 21.4 14.6 17.5 32.5 38.5 30.8 47.6  33.3 45.5 45.2 44.2 ns 
   P<0.01            
               
Overall 67.2 23.7 32.3 29.9 32.8 35.0 32.2 55.7  36.6 43.0 42.0 39.6 P<0.01 
               
 
Intensity ( 1 – 10) - (Score 0=absent are excluded, 1= bearable and 10=unbearable) 
1 2 3 4 5 6 Initial(1-6) TREATMENT 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
               
Standard dose BCG 6.09 2.66 5.21 2.59 5.16 2.54 4.81 2.88 6.00 2.29 5.14 2.88 5.36 2.60 
LD BCG 3.55 1.64 4.56 2.22 5.25 2.96 5.25 2.53 4.73 1.49 3.85 1.77 4.53 2.20 
LD BCG+Interferon 4.89 2.47 6.17 2.04 6.14 2.34 5.00 1.83 4.47 1.64 5.00 2.41 5.10 2.09 
 P<0.05  -  -  -  P=0.06  -  -  
               
Overall 4.84 2.46 5.10 2.39 5.37 2.60 5.00 2.43 5.14 1.98 4.67 2.42 5.03 2.36 
               
 7 8 9 Booster (7-9) Overall (1 to 9) (1-6) vs (7-9)   
 Mean SD Mean SD Mean SD Mean SD Mean SD     
               
Standard dose BCG 6.72 1.84 5.90 2.05 5.87 2.42 6.17 2.09 5.65 2.46 P=0.06   
LD BCG 5.00 1.93 4.63 1.60 4.88 2.30 4.83 1.88 4.61 2.12 ns   
LD BCG+Interferon 6.18 2.14 6.00 2.36 6.07 2.27 6.07 2.21 5.48 2.18 P<0.05   
 -  -  -  P<0.05  P=0.001      
               
Overall 6.19 2.01 5.70 2.11 5.73 2.32 5.86 2.14 5.31 2.32 P=0.001   








(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
              
Standard dose BCG 5.00 7.00 5.00 5.00 4.50 5.00 4.50 5.00  7.50 5.50 5.00 7.00 
LD BCG 4.00 3.00 4.00 4.00 4.50 5.00 3.00 4.00  4.50 4.50 4.00 4.50 
LD BCG+Interferon 5.00 4.00 5.00 5.00 5.00 4.00 5.00 5.00  7.00 5.00 6.50 6.00 
KW test P=0.001 - - - - P=0.06 - P=0.06  - - - P<0.05 
              
Overall 5.00 4.00 5.00 5.00 5.00 5.00 5.00 5.00  7.00 5.00 5.00 6.00 










(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
(1-6) vs (7-9) 
               
Standard dose BCG 96.7 31.1 61.7 56.7 58.3 69.5 55.4 88.5  66.0 66.0 73.7 62.5 P=0.001 
LD BCG 82.1 21.4 35.7 50.0 51.9 53.8 30.8 71.4  66.7 35.0 52.6 50.0 ns  
LD BCG+Interferon 83.3 28.6 43.9 35.0 47.5 45.0 48.7 71.4  58.8 70.6 64.5 60.5 ns 
 P<0.05  P=0.05   P=0.05  P=0.05   P<0.05    
               
Overall 89.3 28.2 50.4 48.4 53.5 58.4 47.9 79.4  63.7 61.4 65.9 59.0 P<0.001 




Intensity ( 1 – 10) - (Score 0=absent are excluded, 1= bearable and 10=unbearable) 
 
1 2 3 4 5 6 Initial(1-6) TREATMENT 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
               
Standard dose BCG 3.05 1.84 3.78 2.29 4.21 2.56 3.89 2.27 3.78 2.14 3.55 1.80 3.77 2.19 
LD BCG 2.33 1.03 3.70 2.06 3.00 1.57 3.21 1.67 3.14 1.51 2.88 1.36 3.11 1.58 
LD BCG+Interferon 2.83 1.53 3.44 2.50 3.29 1.68 3.42 1.54 3.94 1.96 3.37 1.71 3.42 1.85 
 -  -  -  -  -  -  P=0.05  
               
Overall 2.86 1.62 3.68 2.29 3.73 2.23 3.62 1.97 3.70 1.98 3.40 1.71 3.55 2.01 
               
 7 8 9 Booster (7-9) Overall (1 to 9) (1-6) vs (7-9)   
 Mean SD Mean SD Mean SD Mean SD Mean SD     
               
Standard dose BCG 3.58 2.06 4.00 1.97 4.43 2.67 3.99 2.24 3.84 2.20 ns   
LD BCG 3.36 1.50 3.86 1.77 3.80 2.10 3.61 1.73 3.27 1.64 ns   
LD BCG+Interferon 4.30 2.54 4.67 2.55 4.50 2.61 4.50 2.53 3.84 2.20 P<0.01   
 -  -  -  -  P=0.06      
               
Overall 3.75 2.12 4.24 2.19 4.34 2.53 4.10 2.28 3.74 2.12 P<0.01   






(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
              
Standard dose BCG 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00  3.00 4.00 4.50 3.00 
LD BCG 3.00 2.00 3.50 2.50 3.00 3.00 2.00 3.00  3.00 4.00 3.00 3.00 
LD BCG+Interferon 3.00 2.50 2.00 3.00 3.00 3.50 3.00 3.00  3.00 4.00 4.00 4.00 
KW test - - - - - - - - - - - - - 
              
Overall 3.00 2.00 3.00 3.00 3.00 3.00 3.00 3.00  3.00 4.00 4.00 4.00 
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Of all patients 
 
% yes 
Treatment 1 2 3 4 5 6  7 8 9 
           
Within 24 hrs           
Standard dose BCG 15.0 41.7 43.3 41.7 48.3 41.1  42.6 38.3 36.8 
LD BCG 17.9 32.1 46.4 44.4 53.8 30.8  52.4 35.0 36.8 
LD BCG+Interferon 16.7 34.1 32.5 38.5 37.5 35.9  27.3 41.2 35.5 
           
Overall 16.2 37.2 40.6 41.3 46.0 37.2  39.6 38.6 36.4 
           
> 24 hrs           
Standard dose BCG 15.0 20.0 13.3 16.7 20.7 14.3  23.4 27.7 36.8 
LD BCG 3.6 3.6 3.6 7.4 0 0  14.3 0 15.8 
LD BCG+Interferon 11.9 9.8 2.5 7.7 7.5 12.8  30.3 29.4 29.0 
           
Overall 11.5 13.2 7.8 11.9 12.1 10.7  23.8 22.8 29.5 
           
 
 





(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
(1-6) vs (7-9) 
               
Standard dose BCG 83.6 8.2 28.3 36.7 58.3 57.6 42.9 78.7  44.7 40.4 41.0 50.0 P=0.001 
LD BCG 64.3 3.6 28.6 25.0 37.0 42.3 30.8 60.7  42.9 55.0 42.1 40.6 ns 
LD BCG+Interferon 59.5 14.3 22.0 17.5 32.5 32.5 28.2 54.8  44.1 44.1 41.9 44.2 ns 
 P<0.05    P<0.05 P<0.05  P<0.05       
               
Overall 71.8 9.2 26.4 28.1 45.7 46.4 35.5 67.2  44.1 44.6 41.6 46.0 P<0.001 
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Of all patients 
 
% yes 
Treatment 1 2 3 4 5 6  7 8 9 
           
Without clot           
Standard dose BCG 8.2 26.7 30.0 45.0 44.1 41.1  40.4 34.0 33.3 
LD BCG 3.6 25.0 21.4 33.3 42.3 23.1  42.9 45.0 42.1 
LD BCG+Interferon 11.9 19.5 17.5 32.5 30.0 23.1  38.2 35.3 35.5 
           
Overall 8.4 24.0 24.2 38.6 39.2 31.4  40.2 36.6 36.0 
           
With clot           
Standard dose BCG 0 1.7 6.7 13.3 13.6 1.8  4.3 6.4 7.7 
LD BCG 0 3.6 3.6 3.7 0 7.7  0 10.0 0 
LD BCG+Interferon 2.4 2.4 0 0 2.5 5.1  5.9 8.8 6.5 
           
Overall .8 2.3 3.9 7.1 7.2 4.1  3.9 7.9 5.6 
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Of all patients 
 
% yes 
Treatment 1 2 3 4 5 6  7 8 9 
           
Within 24 hrs           
Standard dose BCG 4.9 19.3 35.0 56.7 49.1 32.1  43.5 31.8 26.3 
LD BCG 3.6 28.6 22.2 34.6 42.3 28.0  38.1 21.1 42.1 
LD BCG+Interferon 14.3 19.5 17.5 32.5 30.0 23.1  35.3 32.4 38.7 
           
Overall 7.6 21.4 26.8 44.4 41.5 28.2  39.6 29.9 34.1 
           
> 24 hrs           
Standard dose BCG 3.3 5.3 1.7 1.7 7.0 7.5  0 4.5 13.2 
LD BCG 0 0 0 0 0 0  4.8 31.6 0 
LD BCG+Interferon 0 2.4 0 0 2.5 5.1  8.8 11.8 3.2 
           
Overall 1.5 3.2 .8 .8 4.1 5.1  4.0 12.4 6.8 
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(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
(1-6) vs (7-9) 
               
Standard dose BCG 90.2 27.9 46.7 41.7 55.0 52.5 60.7 86.9  57.4 66.0 69.2 60.9 P=0.001 
LD BCG 64.3 21.4 25.0 42.9 48.1 30.8 26.9 60.7  57.1 55.0 42.1 40.6 ns 
LD BCG+Interferon 73.8 31.0 29.3 40.0 52.5 57.5 48.7 66.7  52.9 52.9 51.6 48.8 ns 
 P<0.05      P<0.05 P=0.01       
               
Overall 79.4 27.5 36.4 41.4 52.8 49.6 49.6 74.8  55.9 59.4 57.3 52.5 P<0.001 
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Intensity ( 1 – 10) - (Score 0=absent are excluded, 1= bearable and 10=unbearable) 
 
1 2 3 4 5 6 Initial(1-6) TREATMENT 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
               
Standard dose BCG 3.41 1.73 3.29 1.68 3.72 2.19 3.45 1.73 3.68 2.04 3.79 1.87 3.57 1.87 
LD BCG 2.67 1.03 4.57 0.98 3.42 1.98 3.62 1.76 3.13 1.46 4.57 2.07 3.64 1.71 
LD BCG+Interferon 3.15 1.28 3.92 1.51 3.56 1.71 3.81 1.83 3.83 1.67 3.74 1.63 3.69 1.62 
 -  -  -  -  -  -  -  
               
Overall 3.19 1.47 3.64 1.59 3.60 1.97 3.60 1.75 3.66 1.83 3.87 1.81 3.62 1.76 
               
 7 8 9 Booster (7-9) Overall (1 to 9) (1-6) vs (7-9)   
 Mean SD Mean SD Mean SD Mean SD Mean SD     
               
Standard dose BCG 3.89 1.91 4.42 2.19 5.15 2.48 4.48 2.23 3.88 2.04 P=0.001   
LD BCG 4.33 1.72 3.91 1.92 3.13 1.46 3.87 1.75 3.73 1.72 ns   
LD BCG+Interferon 4.89 2.14 5.78 2.26 5.94 2.52 5.52 2.31 4.30 2.06 P<0.001   
 -  -  P<0.05  P<0.01  P<0.05      
               
Overall 4.30 1.96 4.73 2.25 5.08 2.50 4.69 2.25 3.99 2.00 P<0.001   
               
 







(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
              
Standard dose BCG 3.00 3.00 3.00 3.00 3.00 3.00 3.50 3.00  4.00 4.00 5.00 4.00 
LD BCG 3.50 3.00 5.00 4.00 3.00 3.00 5.00 3.00  4.50 4.00 3.00 4.00 
LD BCG+Interferon 4.00 3.00 3.00 3.00 3.00 3.00 4.00 3.00  5.00 5.00 5.50 5.00 
KW test P=0.06 - P<0.05 - - - - -  - P<0.05 P<0.05 P<0.01 
              
Overall 4.00 3.00 3.00 3.00 3.00 3.00 4.00 3.00  4.00 4.50 5.00 5.00 
              
 
Of all patients 
 
% yes 
Treatment 1 2 3 4 5 6  7 8 9 
           
Within 24 hrs           
Standard dose BCG 16.9 32.7 33.3 42.1 34.5 40.8  48.9 31.8 29.4 
LD BCG 18.5 18.5 35.7 36.0 30.8 24.0  55.0 40.0 33.3 
LD BCG+Interferon 24.4 22.5 17.5 35.0 41.0 28.9  21.2 29.4 36.7 
           
Overall 19.7 26.2 28.9 38.5 35.8 33.0  41.0 32.7 32.9 
           
> 24 hrs           
Standard dose BCG 8.5 9.1 8.3 10.5 17.2 14.3  8.5 31.8 35.3 
LD BCG 0 3.7 7.1 8.0 0 0  0 15.0 5.6 
LD BCG+Interferon 4.9 5.0 22.5 17.5 15.4 18.4  30.3 23.5 13.3 
           
Overall 5.5 6.6 12.5 12.3 13.0 12.5  14.0 25.5 20.7 
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(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
(1-6) vs (7-9) 
               
Standard dose BCG 67.2 18.0 40.7 31.7 40.0 37.3 32.1 60.7  44.7 51.1 51.3 45.3 ns 
LD BCG 53.6 17.9 39.3 35.7 25.9 26.9 30.8 50.0  28.6 40.0 52.6 34.4 ns 
LD BCG+Interferon 69.0 16.7 24.4 25.0 30.0 37.5 30.8 52.4  41.2 55.9 51.6 51.2 ns 
 ns.  ns.  
               
Overall 64.9 17.6 35.2 30.5 33.9 35.2 31.4 55.7  40.2 50.5 51.7 44.6 ns 
               
 
   
 118 
Intensity ( 1 – 10) - (Score 0=absent are excluded, 1= bearable and 10=unbearable) 
 
1 2 3 4 5 6 Initial(1-6) TREATMENT 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
               
Standard dose BCG 6.27 2.69 5.63 2.78 5.79 2.37 5.46 2.62 5.18 2.34 5.39 2.43 5.56 2.51 
LD BCG 4.40 1.67 5.09 1.81 5.20 2.66 5.14 1.95 5.00 2.00 3.13 1.25 4.71 2.02 
LD BCG+Interferon 5.29 2.43 6.00 2.54 4.60 1.90 4.83 1.75 4.80 1.61 5.25 2.42 5.09 2.05 
 -  -  -  -  -  P=0.06  -  
               
Overall 5.57 2.45 5.58 2.49 5.33 2.33 5.23 2.28 5.02 2.03 4.87 2.36 5.25 2.31 
               
 7 8 9 Booster (7-9) Overall (1 to 9) (1-6) vs (7-9)   
 Mean SD Mean SD Mean SD Mean SD Mean SD     
               
Standard dose BCG 5.52 2.16 5.71 1.85 5.80 2.31 5.68 2.07 5.60 2.36 ns   
LD BCG 6.00 2.19 5.00 2.39 4.20 1.69 4.92 2.10 4.78 2.04 ns   
LD BCG+Interferon 6.07 2.50 6.42 2.27 6.19 2.23 6.24 2.28 5.58 2.22 P<0.01   
 -  -  -  P<0.05  P<0.05      
               
Overall 5.78 2.24 5.86 2.12 5.59 2.25 5.75 2.19 5.44 2.27 P<0.05   
               
 







(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
              
Standard dose BCG 5.00 7.00 5.00 6.00 5.50 5.00 5.00 5.00  5.00 5.00 5.00 5.00 
LD BCG 4.00 4.00 5.00 4.50 5.00 4.00 3.00 4.00  5.00 4.50 3.50 4.50 
LD BCG+Interferon 5.00 7.00 5.00 4.50 5.00 5.00 5.00 5.00  7.00 6.00 6.00 7.00 
KW test P<0.05 - - - - - P=0.05   - - P=0.06 P<0.05 
              
Overall 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00  5.00 5.00 5.00 5.00 
              
 
Of all patients 
 
% yes 
Treatment 1 2 3 4 5 6  7 8 9 
           
Within 24 hrs           
Standard dose BCG 8.2 24.1 23.7 23.3 24.1 26.8  24.4 27.7 20.5 
LD BCG 3.7 17.9 29.6 22.2 26.9 23.1  23.8 25.0 31.6 
LD BCG+Interferon 4.8 9.8 15.0 17.5 20.5 25.6  20.6 24.2 23.3 
           
Overall 6.2 18.1 22.2 21.3 23.6 25.6  23.0 26.0 23.9 
           
> 24 hrs           
Standard dose BCG 9.8 15.5 6.8 16.7 12.1 5.4  17.8 23.4 30.8 
LD BCG 11.1 21.4 3.7 3.7 0 7.7  4.8 15.0 21.1 
LD BCG+Interferon 11.9 14.6 10.0 12.5 15.4 5.1  20.6 30.3 26.7 
           
Overall 10.8 16.5 7.1 12.6 10.6 5.8  16.0 24.0 27.3 
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(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
(1-6) vs (7-9) 
               
Standard dose BCG 49.2 14.8 18.6 27.1 13.3 13.8 9.1 41.0  13.0 19.1 15.4 18.8 P<0.01 
LD BCG 60.7 25.0 35.7 35.7 33.3 30.8 38.5 57.1  28.6 35.0 42.1 28.1 P<0.05 
LD BCG+Interferon 50.0 16.7 22.0 10.0 17.5 20.0 20.5 33.3  27.3 29.4 41.9 39.5 ns 
    P<0.05   P<0.01     P<0.05 P=0.06  
               
Overall 51.9 17.6 23.4 23.6 18.9 19.4 19.2 42.0  21.0 25.7 30.3 27.3 P<0.05 
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Intensity ( 1 – 10) - (Score 0=absent are excluded, 1= bearable and 10=unbearable) 
 
1 2 3 4 5 6 Initial(1-6) TREATMENT 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
               
Standard dose BCG 5.44 2.88 4.36 2.69 4.56 2.71 4.63 3.25 3.88 2.70 5.40 3.65 4.65 2.81 
LD BCG 3.86 2.04 3.90 2.51 4.40 2.59 4.56 2.30 3.38 1.30 3.60 1.51 3.96 2.07 
LD BCG+Interferon 3.43 2.51 4.11 2.03 3.75 1.26 4.29 1.60 4.25 1.98 3.88 2.17 3.98 1.92 
 -  -  -  -  -  -  -  
               
Overall 4.35 2.59 4.13 2.37 4.40 2.47 4.50 2.40 3.83 2.01 4.09 2.31 4.22 2.34 
               
 7 8 9 Booster (7-9) Overall (1 to 9) (1-6) vs (7-9)   
 Mean SD Mean SD Mean SD Mean SD Mean SD     
               
Standard dose BCG 4.50 2.74 5.11 1.76 6.33 2.07 5.29 2.17 4.82 2.65 ns   
LD BCG 5.50 2.67 4.86 2.34 5.13 2.10 5.14 2.24 4.29 2.17 P<0.05   
LD BCG+Interferon 4.89 2.67 5.40 2.63 5.46 2.47 5.28 2.51 4.53 2.27 P<0.05   
 -  -  -  -  -      
               
Overall 4.95 2.58 5.15 2.20 5.56 2.24 5.24 2.31 4.55 2.38 P<0.01   
               
 







(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
              
Standard dose BCG 5.00 5.00 3.00 4.50 3.50 3.00 5.00 4.00  4.50 5.00 6.00 5.00 
LD BCG 4.00 3.00 3.00 3.00 4.00 3.00 3.50 3.00  5.50 4.00 5.00 5.00 
LD BCG+Interferon 4.00 2.00 4.00 4.00 5.00 4.00 3.50 4.00  5.00 5.00 4.00 5.00 
KW test - - - - - - - -  - - - - 
              
Overall 4.00 3.00 3.00 4.00 4.00 3.00 4.00 4.00  5.00 5.00 6.00 5.00 
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(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
(1-6) vs (7-9) 
               
Standard dose BCG 23.0 8.2 6.8 5.0 8.3 6.8 5.4 21.3  6.4 8.5 7.7 6.3 P<0.05 
LD BCG 17.9 10.7 7.1 7.1 7.4 3.8 3.8 14.3  4.8 5.0 15.8 9.4 ns 
LD BCG+Interferon 35.7 9.5 2.4 5.0 7.5 5.0 2.6 19.0  17.6 20.6 6.5 23.3 ns 
             P<0.05  
               
Overall 26.0 9.2 5.5 5.5 7.9 5.6 4.1 19.1  9.8 11.9 9.0 12.2 ns 
               
 






(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
(1-6) vs (7-9) 
               
Standard dose BCG 65.6 6.6 25.4 16.7 21.7 23.7 12.5 45.9  29.8 40.4 46.2 42.2 ns 
LD BCG 35.7 7.1 10.7 14.3 14.8 3.8 11.5 25.0  14.3 30.0 26.3 21.9 ns 
LD BCG+Interferon 57.1 9.5 12.2 25.0 25.0 27.5 20.5 42.9  41.2 41.2 35.5 44.2 ns 
 P<0.05     P=0.05         
               
Overall 56.5 7.6 18.0 18.8 21.3 20.8 14.9 40.5  30.4 38.6 38.2 38.1 ns 
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Intensity ( 1 – 3) - (Score 0=absent are excluded 
 
1 2 3 4 5 6 Initial(1-6) TREATMENT 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
               
Standard dose BCG 1.25 0.50 1.00 0.00 1.10 0.32 1.08 0.28 1.21 0.80 1.00 0.00 1.10 0.43 
LD BCG 1.00 0.00 1.33 0.58 1.00 0.00 1.25 0.50 1.00 . 1.00 0.00 1.12 0.33 
LD BCG+Interferon 1.25 0.50 1.40 0.55 1.00 0.00 1.20 0.42 1.18 0.41 1.13 0.35 1.17 0.38 
 -  P<0.05  -  -  -  -  -  
               
Overall 1.20 0.42 1.13 0.34 1.04 0.20 1.15 0.36 1.19 0.63 1.06 0.24 1.13 0.40 
               
 7 8 9 Booster (7-9) Overall (1 to 9) (1-6) vs (7-9)   
 Mean SD Mean SD Mean SD Mean SD Mean SD     
               
Standard dose BCG 1.21 0.43 1.11 0.32 1.11 0.32 1.14 0.35 1.11 0.39 ns   
LD BCG 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00 1.06 0.25 ns   
LD BCG+Interferon 1.00 0.00 1.07 0.27 1.36 0.92 1.13 0.52 1.15 0.45 ns   
 -  -  -  -  -      
               
Overall 1.10 0.30 1.08 0.27 1.18 0.58 1.12 0.40 1.12 0.40 ns   
               
 







(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
              
Standard dose BCG 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00  1.00 1.00 1.00 1.00 
LD BCG 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00  1.00 1.00 1.00 1.00 
LD BCG+Interferon 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00  1.00 1.00 1.00 1.00 
KW test - - - - - - -   - - - - 
              
Overall 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00  1.00 1.00 1.00 1.00 
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(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
(1-6) vs (7-9) 
               
Standard dose BCG 73.8 8.2 25.4 31.7 28.3 27.1 17.9 54.1  38.3 40.4 43.6 43.8 ns 
LD BCG 39.3 10.7 14.3 21.4 22.2 11.5 7.7 32.1  14.3 30.0 26.3 21.9 ns 
LD BCG+Interferon 61.9 12.2 24.4 25.0 32.5 33.3 23.1 54.8  35.3 44.1 35.5 41.9 ns 
 P<0.01              
               
Overall 62.6 10.0 22.7 27.3 28.3 25.8 17.4 49.6  32.4 39.6 37.1 38.1 P=0.06 
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Intensity ( 1 – 4) - (Score 0=absent are excluded) 
 
1 2 3 4 5 6 Initial(1-6) TREATMENT 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
               
Standard dose BCG 1.40 0.55 1.07 0.26 1.11 0.46 1.00 0.00 1.13 0.34 1.00 0.00 1.09 0.32 
LD BCG 1.67 1.16 1.75 1.50 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00 1.21 0.72 
LD BCG+Interferon 1.40 0.89 1.30 0.68 1.10 0.32 1.15 0.38 1.15 0.38 1.22 0.44 1.20 0.48 
 -  -  -  -  -  -  -  
               
Overall 1.46 0.78 1.24 0.69 1.09 0.37 1.06 0.23 1.13 0.34 1.10 0.30 1.14 0.46 
               
 7 8 9 Booster (7-9) Overall (1 to 9) (1-6) vs (7-9)   
 Mean SD Mean SD Mean SD Mean SD Mean SD     
               
Standard dose BCG 1.50 0.86 1.00 0.00 1.29 0.77 1.26 0.68 1.15 0.50 P<0.05   
LD BCG 1.00 0.00 1.33 0.82 1.40 0.89 1.29 0.73 1.24 0.71 ns   
LD BCG+Interferon 1.08 0.29 1.60 0.83 1.91 1.22 1.53 0.89 1.33 0.69 P<0.05   
 -  -  -  -  -      
               
Overall 1.30 0.68 1.27 0.64 1.52 0.97 1.36 0.77 1.23 0.61 P<0.01   
               
 







(1 to 9) 
1 2 3 4 5 6 Initial 
(1-6) 
 7 8 9 Booster 
(7-9) 
              
Standard dose BCG 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00  1.00 1.00 1.00 1.00 
LD BCG 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00  1.00 1.00 1.00 1.00 
LD BCG+Interferon 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00  1.00 1.00 1.00 1.00 
KW test P<0.05 - - - - - - -  - - - - 
              
Overall 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00  1.00 1.00 1.00 1.00 
              
 
10. Lassitude  
0 - Hardly any difficulty in getting started. No sluggishness 
1 - Difficulties in starting activities 
2 - Difficulties in starting simple routine activities, which are carried with effort 
3 - Complete lassitude. Unable to do anything without any help 
 
11. Disturbed work and activities 
0 - No difficulties 
1 - Thoughts and feeling of fatigue or weakness related to activities 
2 - Loss of interest in activity; hobbies or work-either directly reported by the patient, or indirectly listlessness 
3 - Decrease in actual time spent in activities or decrease in productivity  
4 - Stopped working because of present illness and treatment 
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Section C. Efficacy analysis 
At the time of the interim analysis, it was realized that there was significantly lower 
toxicity in both low dose BCG arms and a borderline statistically significant difference 
between standard dose BCG and low dose BCG plus IFNα (Table 26). As the eligible 
number of new cases in Singapore is low, the protocol was amended, with Institutional 
Review Board and Ethics Committee approval, to stop recruitment in the low dose BCG 
arm. Subsequent patients were randomized to the standard dose and low dose BCG plus 
IFNα arms. 
 Follow up 9 months 
(n=65) (%) 
Follow up 20 months 
(n=62) (%) 
   
Standard dose BCG 32 48 
Low dose BCG 12 24 
Low dose BCG and IFNα 12 12* 
   
 * p=0.035, Mann Whitney test 
 
Table 26. Interim analysis: Recurrence rate  
 
1. Recurrence 
Of a total of 140 patients recruited for this trial, there were 11 exclusions. Nine patients 
were excluded from analysis in the evaluable group analysis because they received less 
than 3 therapeutic instillations and 2 others because they were lost to follow-up, less 
than 3 months after entry into the study.  Of the 9 patients who received less than 3 
therapeutic instillations, 4 patients withdrew from the study before receiving any 
instillations, 1 withdrew for no obvious reason, 2 were understaged at time of entry 
and 2 withdrew because of toxicity (severe haematuria following traumatic 
catheterization, TB orchitis).  Nevertheless, all these patients were included in the 
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intention-to-treat group analysis, the results of which are also presented below. 
Additionally, all the patients who developed systemic side effects e.g. polyarthritis and 
eye symptomology were asked to discontinue treatment but as this usually occurred 
after the 4th instillation, these patients were included in the evaluable group for efficacy 
data analysis. 
Patient and tumour profiles were similar in all 3 arms, except for a preponderance of 
females and grade 3 tumours in the combination therapy arm (Table 27). In this high-
risk group, 77% of the patients had CIS or T1 disease and the rest had multiple or 
recurrent problematic Ta disease.  









LD + IFNα 
(n=41) 
     
Mean age (SD) 65.0 (11.4) 64.5 (11.8) 65.4 (10.4) 65.6 (11.8) 
     
Male 80.2 81.4 89.7 71.1 
     
History of recurrence (+) 45.2 47.4 37.9 47.4 
     
History of TB or Vaccination 
(+) 58.7 55.4 65.5 58.3 
     
Stages of tumour     
CIS 12.7 13.6 10.3 13.2 
Ta 23.0 20.3 20.7 28.9 
T1 46.0 49.2 41.4 44.7 
CIS+Ta/T1 18.3 16.9 27.6 13.2 
     
Grade of tumour     
G1 20.6 22.0 17.2 21.1 
G2 47.6 45.8 58.6 42.1 
G3 31.7 32.2 24.1 36.8 
     
Figures are in percentage (%) 
LD - Low dose BCG 
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The numbers of patients in each arm were different because of the amendment of the 
study from a 3-arm to 2-arm design and the trial statistician’s advice to retain the 
original randomization charts (omitting Arm B alone). Amongst evaluable patients, the 
difference in time to recurrence was 15 months or more longer in patients who 
received low dose BCG or low dose BCG and interferon alpha compared with standard 
dose BCG, (Table 28). The probability of being recurrence-free at 5 years follow-up 
was also significantly lower in the BCG and interferon alpha group (84.8%) compared 
with the standard dose BCG group alone (53.3%). 
Table 28. Mean time to recurrence (in months) 
 
Mean time to recurrence & 95% CI  
Intention-to-treat (N=140) Evaluable cases (N=129) 
     
Standard dose 60.9 (48.1-73.7) 59.8 (46.7-72.9) 
Low dose 76.1 (61.9-90.3) 78.5 (64.7-92.4) 
LD + interferon 73.9 (64.3-83.6) 
Log rank 
(p=0.11) 75.7 (66.4-85.0) 
Log rank 
(p=0.04) 
     
Overall 73.4 (65.2-81.5)  74.1 (65.8-82.3)  
     
Probability of recurrence-free at 5 years  
Intention-to-treat (N=140) Evaluable cases (N=129) 
     
Standard dose 54.9 % 53.3 % 
Low dose 71.4 % 73.8 % 
LD + interferon 82.5 % 
Log rank 
(p=0.11) 84.8 % 
Log rank 
(p=0.04) 
     
Overall 67.6 %  68.3 %  
     
 
LD - Low dose BCG 
 
 
At the time of last follow-up, the recurrence risk in the combination therapy arm was 
significantly lower compared with the standard dose arm (Table 29). Possibly because of 
small numbers, a significant reduction was not noted between the low dose BCG alone 
and standard dose BCG arms. 
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Table 29. Recurrence rates and hazard ratios by treatments 
 Recurrence rates Rate ratios (95% CI) 
   
Status at 12 months (among those who completed 12-month FU) 
Standard dose* 14.6 1.00 
Low dose 10.7 0.74 (0.19-2.84) 
LD + interferon 5.6 0.38 (0.08-1.83) 
   
Overall 10.7  
   
Status at 24 months (among those who completed 24-month FU) 
Standard dose* 29.7 1.00  
Low dose 15.4 0.52 (0.17-1.63 
LD + interferon 12.0 0.40 (0.11-1.45) 
   
Overall 23.8  
   
Status at last FU (Using Cox regression method) 
 Hazard rates Adjusted HR ratio (95% CI) 
Standard dose* 29.7 1.00 
Low dose 28.1 0.40 (0.16-1.02) 
LD + interferon 13.6 0.35 (0.13-0.95) 
   
Overall 24.8  
   
*Reference group; Adjusted for age, sex, tumour type, grade of tumour, hx of recurrence, hx of TB or BCG 




The recurrence-free functions by treatment arm (Kaplan Meyer curves) show a clear 
reduction in recurrence events in the combination therapy arm (Fig. 44). Although there 
appears to be an advantage for low dose BCG alone compared with standard dose BCG 
initially, this seems to decrease with time, whereas that of the combination therapy 
persists. 
 


























B-Low Dose BCG      
-censored
A-Standard dose BCG




Figure 44. Recurrence-free functions (KM curve) by treatments, based on status 
at last follow-up 
 
2.  Progression in patients 
There were 13 progressions amongst these 130 patients. There were 7 progressions in the 
standard dose BCG arm, and 3 each in the low dose BCG arm and the low dose BCG 
and IFNα arm i.e. 12%, 10% and 7% in standard dose BCG, low dose BCG and the 
combination therapy arms respectively. Four patients in the standard dose BCG arm 
underwent cystectomy, as did 2 patients in the low dose BCG arm. None of the patients 
in the combination therapy arm underwent cystectomy. 
3.  Maintenance therapy 
In all, 17 patients agreed to undergo maintenance therapy.  None completed a full 3-year 
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justified in the presence of mounting local toxicity in responders. Eight patients from the 
standard dose BCG arm received maintenance therapy; 3 developed superficial 
recurrences: 1 was treated by transurethral resection alone, another by transurethral 
resection followed by mitomycin C and the third patient also had progression to muscle-
invasive disease and underwent cystectomy but has developed metastatic disease. 
Likewise, 6 patients from the low dose BCG arm received maintenance therapy; 2 
developed recurrences treated by transurethral resection but 1 subsequently progressed 
and underwent cystectomy. Three patients from the combination therapy arm underwent 
maintenance therapy; 1 developed a superficial recurrence in a diverticulum and 
underwent a diverticulectomy. There has been 1 unrelated mortality but no cancer-
specific mortality in the patients who received maintenance therapy. 
4.  Mortality 
There were 32 deaths in this study; 23 were due to other causes and were unrelated to 
bladder cancer or its therapy. There were 7, 0 and 2 bladder cancer-specific mortalities in 
the standard dose, low dose and combination therapy arms respectively. 
5. Extravesical recurrence 
Extravesical recurrence in the renal pelvis, ureter or urethra, in the absence of a 
recurrence in the bladder, was not an outcome measure. Nevertheless, there have been 6 
upper tract recurrences without disease in the urinary bladder; none in the standard dose 
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Part I 
Section A. Development of a protocol for the assay of cytokines in the urine of 
BCG-treated patients  
Although much is now known about the effects of BCG immunotherapy on the 
bladder, the exact mechanisms involved have yet to be elucidated, necessitating 
clinical regimens, which are empirical rather than based on immunological data 
(Lamm et al 1992). An important source of immunological data has been the 
monitoring of urinary cytokines and soluble intercellular adhesion molecules produced 
during BCG therapy (Bettex-Galland et al 1991; Bohle et al 1990; De Boer et al 1991; 
De Boer et al 1992; Schamhart et al 1992; Jackson et al 1992). Some of these markers 
are of particular interest as they may also be of predictive value with respect to initial 
response and relapse of disease (Fleischmann et al 1989; Jackson et al 1995). This is 
especially important as a significant number of non-responding patients, such as some 
patients with CIS of the bladder, progress to more aggressive disease during therapy 
and initial monitoring (Herr 1992). Indeed one of the main criticisms of using a second 
course of BCG immunotherapy for initial non-responders is the high risk of 
progression in those who subsequently fail therapy (Coplen et al 1990; Bretton et al 
1990). The early identification of unfavorable groups may allow alternative therapies 
to succeed before cure becomes impossible. 
There have been numerous reports in the literature on urinary cytokine secretion in 
normal, diseased and BCG-treated patients but the investigators have used different 
methods for processing, storing and assaying the urine samples. This makes 
comparisons between studies difficult and has sometimes led to divergent views. For 
example, IFNγ, a cytokine which may play an important role in the expression of MHC 
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Class II and ICAM-1 in bladder tumours has been variously reported to be present 
(Prescott et al 1990) and absent (De Boer et al 1992). Likewise, urinary IL-2 has been 
reported to be a prognostic marker in some studies (Haaff et al 1986; Fleischmann et al 
1989; de Reijke et al 1996) but not in others  (Jackson et al 1995).  
Furthermore, as the importance of these immunological markers is gaining general 
attention, multicentre studies are being contemplated. To diminish inter-observer 
variation, the processing of urine samples would need to be standardized. Also, the 
storage of specimens prior to bulk delivery to a processing centre is more economical. 
It was therefore important to evaluate the effects of delay in processing and ambient 
temperature on samples sent by post and to determine whether storage at -20oC 
temperature is sufficient or more expensive  -70oC freezers required. 
It is reasonable to expect that as in other biological systems, numerous factors 
including pH, ambient temperature, duration of storage, soluble receptors, specific and 
non-specific inhibitors and urinary matrix proteins may influence the quantification of 
cytokines (Fleischmann et al 1989; De Jong et al 1990; Liao et al 1984; Thorpe et al 
1992; Anon 1992). 
 
Stability of cytokines and sICAM-1 
IL-2, IL-6, IL-10, IFNγ and sICAM were stable in both dialysed and non-dialysed 
urine at 4oC and -20oC. They also appeared to be fairly stable at 22oC in non-dialysed 
urine with the exception of IL-10 and IFNγ.  The rapid degradation of the cytokines 
and sICAM-1 in dialysed urine at 22oC may be related to the loss of small proteins or 
other molecules, which play a role in stabilizing the urinary cytokines.  In addition, 
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enzymatic degradation of these proteins by proteases, released as a result of 
inflammation, may be enhanced at a neutral pH. 
 
Effect of dialysis  
The recovery of IL-2 was not enhanced by dialysis when assayed with the Amersham 
kit, suggesting that the kit performed relatively independently of sample pH in the 
range of 6.26 to 7.22. However, the yield of IL-2 from non-dialysed urine was almost 
twice that of dialysed urine when using the Medgenix kit. This result may have 
occurred because the Medgenix kit was detecting isotopic IL-2 fragments as well, 
which may have been removed by dialysis. Dialysis dramatically increased the yield of 
sICAM-1 from acidic urine but not urine of neutral pH.  It is therefore probable that 
the effect of pH on the quantification of urinary ICAM-1 using the BBE1/2 kit is 
considerable. The detection of IL-6 and IL-10 were not influenced by dialysis. 
 
Removal of inhibitors by dialysis 
With the current understanding of cytokine autoregulatory mechanisms, it is not 
surprising that the urine of patients treated serially with BCG may contain large 
amounts of inhibitory factors produced to limit the well-documented cytokine burst 
caused by each instillation. In a bioassay for IL-2, using the CTLL-16 cell line, no 
biological activity could be detected in IL-2 spiked samples of non-dialysed urine in 
contrast to high activity in dialysed urine (De Jong et al 1990). In this study using 
sandwich-ELISA assays, the detectable quantities of IL-2 between dialysed and non-
dialysed acidic and neutral pH samples was small or absent, This is probably because 
monoclonal sandwich-ELISA assays may detect both biologically active as well as 
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inactive cytokine. The total IL-2 production in this context may be of greater 
relevance. It has been reported that the combined quantity of IL-2 and IL-2 inhibitor 
complex in the urine is predictive of response to BCG therapy but the quantity of 
biologically active IL-2 alone is not (Fleischmann et al 1989). Nevertheless, these 
inhibitors are capable of blocking the attachment of detecting primary monoclonal 
antibodies. The use of oligoclonal ELISA systems comprising several monoclonal 
antibodies directed at distinct epitopes of the target molecule therefore considerably 
increased the yield of IL-2. The oligoclonal system was reported by its manufacturers 
to be unaffected by the presence of soluble IL-2 receptors. Therefore, a part of the 
almost 2-fold increase in detectable urinary IL-2 with this kit may have been due to the 
presence of this receptor in the urine. However, dialysis decreased the quantity of IL-2 
detected by the oligoclonal system, suggesting that IL-2 fragments were also being 
detected.  
 
The presence of INFγ in the urine of BCG-treated patients has been disputed (De Boer 
et al 1992). Its presence has since been confirmed (Jackson et al 1995). The difficulty 
with its detection was believed to be due to pH-lability (Prescott et al 1990). However, 
dialysis improved the recovery of IFNγ in urine of neutral pH by almost 100%.  As 
dialysis through a 10 kDa membrane made a large difference in detection in the control 
samples, there is probably a dialysable inhibitor of low molecular weight, perhaps 
resembling the 11 to 12 kDa inhibitor of IL-2 (Honda et al 1985). There is evidence 
that inhibitory soluble receptors to INFγ exist (Larrick et al 1992). It remains to be 
proven whether this is the case here.  
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Other circumstantial evidence of the possible importance of IFNγ inhibitors may be 
gleaned from the anomalous IFNγ stability assay of Patient 1 (Fig. 7b). The level of 
IFNγ in the dialysed samples incubated at 22oC increased in an exact temporal contrast 
to the decline seen for all the cytokines, including that of IFN γ for the other patients, 
at that temperature. A possible explanation is that there may be a specific inhibitor-
complex of IFNγ in the urine, which is more unstable than IFNγ itself and whose 
degradation is accelerated and/or is removed by dialysis in the same way as the other 
cytokines. The degradation of this inhibitor complex may release IFNγ or epitopic 
IFNγ fragments and small proteins or other molecules which act to stabilise IFNγ in the 
same manner as that observed for most of the cytokines in non-dialysed urine. This 
would result in an increased yield of IFNγ with time. Why this effect was not observed 
in all the patient samples remains unknown.  As the assay used to detect IFNγ was 
oligoclonal, this inhibitor complex presumably blocked several epitopes or else caused 
allosteric inhibition by changing the conformation of the cytokine. It is therefore 
unlikely to be the soluble receptor of IFNγ. However, the other possibility is that 
epitopic fragments of IFNγ, from degradation, were being measured by the oligoclonal 
ELISA assay but this alone cannot explain the improved recovery of IFNγ after 
dialysis of urine of neutral pH. 
 
Effect of freezing non-dialysed urine 
The freezing of acid urine samples resulted in variable damage to IL-2, ICAM-1 and 
IFNγ, which could not be completely reversed by dialysis after thawing. This loss, 
which ranged from a 10% to a 30% loss, was not seen with urine samples of neutral 
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pH. This data verifies the report that dialysis of urine before freezing improves the 
yield of IFNγ (Prescott et al 1990). 
 
Conclusion 
On the basis of these studies, some simple recommendations are suggested. Fresh urine 
should be stored at 4oC as soon as possible after collection. Centrifugation of the 
specimen will remove cells and debris, which may interfere with the accuracy of 
photometric sandwich-ELISA assays.  Undialysed specimens can safely be transferred 
at 4oC to a central facility. Samples should preferably be dialysed to a neutral pH 
before freezing. In the absence of comparative data about the various commercially 
available ELISA kits, investigators should select kits cautiously. 
 
Section B.  
(I) Changes in Urinary Cytokines and soluble Intercellular Adhesion Molecule-1 
in Patients with Carcinoma-in-situ after BCG Immunotherapy 
Therapeutic regimens differ widely and remain empirical as the mechanisms of action 
of BCG in promoting local immunopotentiation of the bladder wall are incompletely 
understood (Jakse et al 1992). 
Many studies have demonstrated that instillation of BCG into the bladder allows 
adherence to damaged urothelial lining, via fibronectin (; Kavoussi et al 1990; Cheng et 
al 1994; Zhang et al 2002), an extracellular matrix protein found on the basement 
membrane (Pode et al 1986) and that this mechanism could be modulated by anti-
clotting agents (Hudson et al 1990 & 1991). However, this inhibitory effect of aspirin 
and coumarin does not appear to have any effect on clinical efficacy (Witjes  et al 1993). 
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Endocytosis by urothelial cells may subsequently occur (Becich et al 1991). The 
interaction of BCG organisms with tumour cells, normal cells and resident macrophages 
leads to the release of chemokines and chemotactic factors, which activate the 
macrophages to produce inflammatory cytokines. A large infiltrate of immunologically 
active cells occurs, which is characterized primarily by infiltration of activated T-cells, 
polymorphonucleocytes and to a lesser extent of macrophages in the lamina propria of 
the bladder wall (el-Demiry et al 1987; van der Meijden et al 1988; Prescott et al 1989 & 
1992). These cells produce a cocktail of cytokines, including IL-1, IL-2, IL-6, IL-8, IL-
10, IL-12, TNFα and IFNγ, which are readily detectable in the urine in the first few 
hours after BCG instillations. The cytokines may induce and augment the expression of 
major histocompatibility complex (MHC) class I and II -type antigens (Jackson et al 
1992) and intercellular adhesion molecule-1 (ICAM-1) on patients' tumour cells 
(Esuvaranathan et al 1993). In vitro, these aid the interaction of lymphokine-activated 
killer (LAK) cells and tumour infiltrating lymphocytes (TIL) with tumour cells resulting 
in tumour ablation (Jackson et al 1992). Also, fibronectin has been reported to be present 
on LAK cell membranes and by interacting with BCG, may mediate the killing of 
tumour cells via an apoptotic mechanism (Shemtov et al 1995). In addition, IFNγ may 
exert direct cytostatic and cytotoxic effects on bladder cancer cells (Hawkyard et al 
1992) as well as indirect effects via downregulation of epidermal growth factor receptor 
(Alexandroff et al 1995). Apart from these non-specific immunological responses, BCG 
activated CD4+ T-cells in the murine model respond specifically to bladder cancer cells, 
which have been induced to express MHC class II with IFNγ, by producing IL-2 and 
TNFα (Lattime et al 1992). 
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In this study, most patients who received intravesical BCG immunotherapy underwent 
a local immunological response with the accompanying secretion of cytokines in their 
urine. Most of these patients did not have detectable levels of IL-2, IL-4, IL-6, IL-8, 
TNFα, IFNγ  and soluble ICAM-1 prior to immunotherapy.  The quantity produced in 
the first 12 hours after each instillation varied considerably between patients. On 
average, there was a rising trend, which peaked after the final instillation and 
represented a 6-fold to a 140-fold increase over this period. The exception to this was 
IL-4, which was not detectable after BCG immunotherapy. Some patients did not 
produce any cytokines even after their final instillation. Of note is that 5 of these 11 
patients did not produce any IL-2 after their final instillation. Three of these patients 
however had satisfactory resolution of their disease but 2 did not. All but one patient 
produced soluble ICAM-1. The disease of the patient who lacked soluble ICAM-1 did 
not respond to therapy. 
IFNγ has been variously reported to be present (Prescott et al 1990) or absent (De Boer 
et al 1992) in the urine of BCG treated patients. This report confirms its presence. As 
IFNγ is acid-labile, fresh urine must be rapidly dialysed to a neutral pH to preserve 
IFNγ. All but one patient, a non-responder, showed a several-fold increase between 
first and sixth week instillations, implying an important role for this cytokine. 
It has been noted that the combined predictive power of IL-2 and IL-2 inhibitors in the 
urine was statistically significant (Fleischmann et al 1989). The dialysis of urine for 24 
hours, as was done in this study, was reported to remove most of these inhibitors (De 
Jong et al 1990). It is therefore surprising that no IL-2 could be detected in the urine of 
3 patients whose tumours responded to therapy. It is probable that other inhibitors, 
which were not removed through this dialysis process, exist. One such inhibitor could 
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be a human urine-derived protein complex (IL-2-IN) which has been partially 
characterized as a 75 kDa complex (Fleischmann et al 1990).  
IL-4 is a product of the TH2 subset of T-helper lymphocytes. Its absence in all the 
patients and the presence of IFNγ and IL-2 suggest that intravesical BCG preferentially 
elicits a predominantly TH1 response. It should be noted that studies on cloned human 
T cell lines have revealed that mycobacteria selectively induce a TH1 cytokine 
secretion profile (Haanen et al 1991). 
IL-6 promotes IL-2 production and differentiation of cytotoxic lymphocytes. However, 
non-responders had a much higher initial response (in the absence of bacteriuria) and 
produced more IL-6 than the responders (p<0.02). Administration of IL-6 in mice 
injected intravenously with transplantable murine tumours decreases the appearance of 
lung nodules. Yet IL-6 in vitro may act as an autocrine growth factor for renal cell 
carcinoma and multiple myeloma (Miki et al 1989; Hata et al 1990). Urinary IL-6 
levels are related to stage in bladder neoplasms and significantly decrease after surgical 
removal of the tumours. These observations support the hypothesis that the tumour 
itself is the primary source of IL-6 - the greater the tumour burden, the more the IL-6 
secretion. This could explain the higher levels seen in non-responders presuming that 
they had a greater tumour burden. (Tumour burden correlates strongly with stage, 
which is itself one of the most consistent independent factors in bladder cancer 
prognosis.) IL-6 was first discovered in a bladder tumour cell line. Also, urothelial 
cells would not be unique in this ability to secrete cytokines; human epidermal cells 
and epidermoid carcinoma cell lines, hepatocarcinoma cell lines, pituitary adenomas, 
and retinal pigment epithelial cells have been demonstrated to do the same. A second 
source of IL-6 would of course be activated macrophages and lymphocytes themselves. 
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This could explain the 5-fold rise seen during BCG therapy. In vitro, BCG organisms 
can directly induce some human bladder cancer cell lines to produce cytokines. This 
raised the other intriguing possibility that BCG may upregulate IL-6 production in 
urothelial cells in vivo. 
As IL-8 is a chemokine for neutrophils, its presence and increasing trend during 
therapy in both responders and non-responders match the finding that large numbers of 
neutrophils enter the bladder wall and are found in the urine after BCG instillations (el-
Demiry et al 1987; de Boer et al 1991; Prescott et al 1992). 
TNFα, a product of macrophages, showed large increases only in the latter weeks of 
therapy. It has been postulated that the early rise seen soon after each BCG instillation 
may indicate activation of macrophages by BCG organisms (Bohle et al 1990; De Boer 
et al 1992).24,45 If this is so, the recruitment of monocytes into the bladder wall and the 
increased adherence of BCG organisms to exposed fibronectin in the inflamed and 
eroded urothelium as therapy progresses may underlie the increasing trend noticed. 
Soluble ICAM-1 was strongly induced by BCG immunotherapy, appearing in only 2 
patients after the first instillation and in all but one patient after the final instillation. It 
would appear that the expression of adhesion molecules, which serve as a ligand for 
activated leukocytes such as LAK cells, would decrease the survival potential of a 
tumour. However, some studies have correlated ICAM-1 expression with an increased 
propensity for tumour metastasis (Natali et al 1990;  Tsujisaki et al 1991).141,188 Others 
have shown that the metastasis of human tumours is less common when MHC class I 
antigens and ICAM-1 are highly expressed (Vanky et al 1990).198 It is possible that 
ICAM-1 expression has differing roles in the metastatic potential of tumours 
depending on tumour type, size, local and stromal factors and the confounding effects 
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of shed (soluble) ICAM-1. In this small study, a significant difference was noted in the 
mean ICAM-1 production after the final BCG instillation in responders and non-
responders. Furthermore, all responders produced soluble ICAM-1. Significantly, one 
non-responder who had induction of all the other inducible cytokines had no ICAM-1. 
In vitro studies have shown that lymphokine-activated killer mediated cytolysis of 
bladder cancer cells correlated well with IFNγ-induced ICAM-1 expression (Jackson et 
al 1992). Also, antigen presentation by epithelial cells to T-lymphocytes requires the 
presence of both MHC Class I and ICAM-1 expression. It was therefore likely that the 
detection of ICAM-1 in the urine of these patients probably signified an important 
intermediary role in the killing of tumour cells. 
 
Conclusion 
BCG induces many, predominantly but not exclusively Th1 cytokines and adhesion 
molecules and receptors. These cytokines are known to modulate the inflammatory 
response and the components of the cellular immune system responsible for tumour 
recognition and lysis, as described above. Low or undetectable levels of some of these 
mediators such as IFNγ or ICAM-1 appear to be associated with non-response to 
therapy. 
 
Section B.  
(II) IL-6 Studies 
IL-6 is detectable in the urine of BCG treated patients. It is often present before 
treatment and increases following BCG therapy (de Boer et al 1992). It has generally 
been assumed that the cytokines found in urine following BCG treatment are produced 
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by host leukocytes. However, it has been noted that IL-6 in urine correlates with the 
stage of bladder cancer and is absent after resection of the tumor (Seguchi et al 1992). 
It is therefore possibly related to either host-tumor interaction or tumor bulk; the latter 
possibility suggests tumor cell production. Furthermore it is known that certain bladder 
carcinoma cell lines have the capacity to secrete IL-6. Indeed, the bladder carcinoma 
cell lines T24, RT4 and 5637 were among the first epithelial cell lines recognized to 
produce IL-6 (Rawle et al 1986). Messenger RNA for IL-6 has also been reported in 
high grade de novo bladder carcinomas and 2 bladder carcinoma cell lines (Meyers et 
al 1991; Kaashoek et al 1991).  
These studies demonstrate the constitutive expression of IL-6 by many TCC cell lines 
and naturally arising tumor specimens. Furthermore, the exposure of bladder tumor to 
IFNγ or BCG in vivo and in vitro upregulates the expression and secretion of IL-6. 
This was true both for monolayer cultures and multicellular spheroids, in which 
upregulation was also seen in the deeper cell layers. 
Contrary to the report of Meyers (Meyers et al 1991), the majority of established 
bladder carcinoma cell lines studied showed constitutive IL-6 secretion. The MGH cell 
line, a subline of the T24 cell line, was found to constitutively secrete IL-6 in contrast 
to the T24 cell line itself, (Schamhart et al 1993) although the T24 cell line is known to 
express mRNA for IL-6 (Yasukawa et al 1987). Furthermore all 7 cell lines could be 
induced to secrete IL-6 on stimulation with IFNγ and the MGH, 5637 and J82 lines 
also, on stimulation with BCG. 
It is interesting that the high grade cell lines showed a greater response to stimulation 
than the low grade lines. It is possible that normal homeostatic mechanisms are lost in 
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high grade tumors, preventing negative feedback from excessive IL-6. Also, there may 
be a causal link with mutations of the p53 tumor suppressor gene, which is known to 
be mutated in some bladder cancer cell lines like J82 (grade 3), but not in RT4 (grade 
1). The p53 gene has transcriptional repressor activity in modulating IL-6 gene 
expression, and some p53 mutants are also known to up regulate IL-6 promoter activity 
(Santhanam et al 1991; Margulies and Sehgal 1993). 
In this study, all 13 patients had an increase in IL-6 secretion during therapy, with a 5-
fold average increase between first and final post-instillation secretion. Shed cells 
showed modest staining, which increased during therapy. Also, in 2 nonresponders, the 
BCG-treated bladder tumors as well as the adjacent urothelium were positive for IL-6. 
Some post-BCG bladder biopsies showed positive IL-6 staining of the urothelial lining 
but negative suburothelial tissues. Human bladder cancer cells grown as multicellular 
spheroids also showed constitutive and enhanced production of IL-6 in response to 
both IFNγ and to BCG. These findings imply that the increase in IL-6 seen during 
BCG immunotherapy is not due only to infiltration and secretion by neutrophils, 
monocytes and macrophages, but also to the urothelial cells themselves. 
Five of 8 fresh bladder tumors were positive for IL-6. These findings corroborate 
previous reports of IL-6 mRNA synthesis in high grade de novo bladder carcinoma 
cells (Meyers et al 1991). Extrapolating these data, it is possible that many more de 
novo bladder tumors secrete IL-6 than has been previously recognized.  
The possibility that urinary IL-6 may be used as a tumor marker for transitional cell 
cancers was investigated. It was realized that IL-10 may also be constitutively secreted 
by bladder tumours (Figs. 23-25). Although 24-hour urinary IL-6 and IL-10 levels 
   
 149 
were generally higher compared with normal controls, they fluctuated during the day 
and overlapped with patients with urinary tract infections. The intermittent secretory 
pattern and overlap, even in IL-6:IL-10 ratios made these unlikely candidates for 
diagnostic markers. 
The report that urinary IL-6 secretion may have prognostic implications for patients 
with invasive bladder carcinomas combined with the present findings suggests that the 
tendency of some bladder carcinomas to secrete IL-6 may have important prognostic 
implications. High levels of urinary IL-6 secretion in patients with CIS may carry a 
poorer prognosis. Possible reasons for this may be a high tumor burden or that the 
more aggressive tumors, possibly related to mutant p53, secrete more IL-6. However, 
reports that IL-6 may function in vitro as an autocrine growth factor in renal cell 
carcinomas (Miki et al 1989; Takenawa et al 1991) may also be relevant to transitional 
cell carcinomas, especially as mRNA for IL-6 receptors has been noted in all de novo 
bladder tumors examined in a large series (Meyers et al 1991). IL-6 and IL-10 
production may be related in an autocrine fashion, as anti-IL-6 applied to human TCC 
cell lines in vitro decreased endogenous IL-10 production (data not shown). 
Conclusion 
Some cytokines such as IL-6 and IL-10 are constitutively secreted by tumours and not 
by inflammatory cells alone. This production can be upregulated by BCG 
immunotherapy. These cytokines may have related, autocrine functions and could 
possibly be of some prognostic value. The potent anti-inflammatory effects of IL-10 
could well be one of the devices used by tumours to cloak themselves from detection 
by the cellular elements of the immune system and may influence the local response to 




Section B.  
(III) ICAM-1 Studies 
This data has demonstrated that intravesical BCG generates an effective host mounted 
immune response. Such a response involves the production by infiltrating leucocytes 
of large quantities of pro-inflammatory cytokines. Furthermore, the neo-expression of 
MHC class II products by bladder tumour cells in monolayer culture (Prescott et al 
1989) was confirmed in these multicellular spheroid studies also (Figs. 28 & 30).  
Several recent reports, using an in vitro tissue culture model of bladder cancer have 
indicated that other molecules may also be induced by the cytokines contained in urine. 
One such molecule, intercellular adhesion molecule-1, is a cytokine-inducible adhesion 
molecule and is one of three known counter-receptors for leucocyte function-
associated antigen-1. Previous studies have indicated that bladder cancer cell lines 
express low levels of ICAM-1 (Jackson et al 1992). However, following stimulation 
with IFNγ or TNFα, ICAM-1 expression rapidly and markedly increased. High levels 
of ICAM-1 expression resulted in significantly increased vulnerability to cytotoxicity 
mediated by IL-2 activated lymphocytes. This cytotoxicity was found to be almost 
entirely LFA-1 dependent, involving the ICAM-1 and ICAM-2 counter-receptors 
localised on the bladder tumour cell. 
This study extends these observations in monolayer cultures to 3-dimensional 
spheroids. This is important because in a monolayer culture, there is obviously a large 
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exposed surface area for cell-cell contact and interaction, which may exaggerate the 
cytotoxic effects observed. The multicellular spheroid more closely resembles a 
tumour in vivo. These studies demonstrate that the data from multicellular spheroids 
are similar to that from monolayer cultures. Cytokine and ICAM-1 upregulation occurs 
with both IFNγ and BCG in the same pattern as for monolayer cultures. Interestingly, 
even cells deep within the spheroid are upregulated, suggesting that the surface 
application of recombinant cytokine or BCG is able to either penetrate deeply or cause 
a chain reaction of cell-to-cell upregulation. The cytotoxic effect of IFNγ on the RT112 
cell line continues, even after the cytokine is removed, possibly because of a bystander 
effect, mediated by the release of perforins or other lysins by damaged neighbouring 
cells, providing some insight into how BCG may be effective in the bladder despite a 
relatively short exposure time. The spheroid-LAK cell interactions demonstrate the 
effectiveness of LAK cell-mediated tumour killing, a mechanism that is probably 
paralleled by active immunopotentiation of the bladder by intravesical BCG. BCG 
incites a vigorous local response in the bladder wall accompanied by mild to severe 
symptoms of bladder irritation. There is a local chronic imflammatory response with 
granuloma formation. An increase in CD4+ve T "Helper" lymphocytes has been 
documented as well as an increase in CD8+ve cytotoxic cells. There is also an increase 
in granulocytes and macrophages. This cocktail of urinary cytokines have complex 
interactions and result in activated lymphocytes, capable of the anti-tumour effects 
demonstrated in these studies. 
In this study, 16 patients treated with BCG immunotherapy showed a conversion of 
their tumour cells from negative to positive ICAM-1 expression. Of two patients with 
weak positivity, one also had low levels of ICAM-1 in his urine, failed therapy and 
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required cysto-urethrectomy at 3 months post treatment to control his disease. The 




Changes in the malignant urothelial itself however, have hitherto been confined to an 
increase in MHC Class II antigen. Detection of ICAM-1 on the surface of detached 
tumour cells is therefore interesting as it reflects expression of an important counter-
receptor to LFA-1. Coupling of ICAM-1 expressing tumour cells and activated 
lymphocytes allows a host of cytotoxic activity both in monolayer cultures as well as 
multicellular microspheroids. Previous studies indicate that there is increased 
vulnerability of cancer cells to IL-2 activated T-lymphocytes (Jackson et al 1992). 
Blocking antibodies to ICAM-1 can markedly reduce this cytotoxicity. Specific tumour 
targeted killing is therefore one of the possible means of BCG activated 
immunotherapy.
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Part II.  
A multicentre, double blind randomized clinical trial of intravesical bacillus 
Calmette-Guérin and interferon alpha-2b in the treatment of superficial bladder 
cancer 
Section A. A comparison of urinary cytokines in low and standard dose BCG 
therapy and low dose BCG with IFNα in a “6+3” schedule for bladder cancer 
This data demonstrates that there is an increasing trend of urinary cytokine production 
during the first 6 therapeutic instillations (the “induction course”). This corresponds 
with the increasing inflammation of the bladder mucosa witnessed during cystoscopy 
and with symptoms of bladder inflammation experienced by patients during therapy. 
There is interestingly, augmented production of these cytokines during the 7th to 9th 
instillations (“the booster course”). This augmented cytokine response resembles the 
secondary immune response, first noticed in antibody production in the humoral 
immune response (Fig. 45) and which forms the rationale for booster inoculations in 
vaccinations against infectious disease. The secondary immune response is 
characterized by a faster response time and a several fold increase in magnitude. The 
cytokine pattern seen after the 7th instillation demonstrates this pattern. The secondary 
immune response usually takes 2 to 3 weeks to develop after primary exposure. Why 
then does it not appear until the booster instillations? 









Fig. 45. The secondary immune response  
This underlies the immune system’s ability to augment its response to rechallenge with 
the same antigen. 
 
 
A likely explanation is that the inflammation caused by BCG during the induction 
course is excessive. It is probable that many anti-inflammatory processes are triggered, 
including the production of the potent TH2 cytokine, IL-10 (Fig. 46). Bearing in mind 
that high levels of IL-10 can induce tolerance, it is important that overstimulation of 
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Fig. 46. Model of TH1-TH2 cytokine interactions 
The 2 groups of cytokines cause undifferentiated TH0 cells into a cellular or humoral 
immune response. 
 
Section B. Toxicity analysis 
In this double-blinded study, reduction in the dose of Connaught strain BCG from 
81mg to 27mg significantly reduced both local and systemic side effects during the 
induction course of the first 6 instillations. However, during the booster course (7th to 
9th instillations), there was no difference in toxicity amongst the 3 arms as would be 
expected in a secondary immune response. There was significantly more toxicity 
during the booster course compared with the induction course but symptoms were also 
self-limiting and tolerable, with most patients being able to continue their normal 
activities. This is the first report of increased local toxicity in patients who had 
previous exposure to tuberculosis or BCG vaccination.  
-
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Although earlier trials in which a 6 instillation only schedule had also shown a 
reduction in local toxicity, there was some concern about a concomitant reduction in 
efficacy. The two dose reduction trials with extended schedules which reported 
equivalent or superior efficacy, were both non-blinded and therefore, their data on 
toxicity could not be assured and both used more intensive schedules of 6 weekly 
instillations followed by either 6 fortnightly booster instillations  (Martinez-Pineiro et 
al 2003) or 24 monthly booster instillations .  
In our study, the addition of IFNα did not increase toxicity in the low dose group 
whilst maintaining comparable if not potentially superior efficacy. Therefore, it 
appears that the combination of low dose BCG and IFNα in a “6+3” schedule could 
become the new standard for high risk superficial bladder cancer if its efficacy is 
confirmed, as it is a less intensive schedule. 
 
Section C. Efficacy analysis 
This Phase IIb trial showed an unexpected benefit in the reduction of recurrences. Both 
time to recurrence and recurrence rates were lower in the combination therapy arm 
compared with the standard dose arm.  The Kaplan Meyer curve for recurrence for the 
combination of IFNα and BCG is very interesting both in terms of the significant 
reduction in recurrence rate as well as the durability of protection compared with the 
BCG alone arms. There have been too few progressions and disease specific 
mortalities in this study to allow any conclusions to be drawn about differences in 
these parameters. However, there is no evidence that the combination therapy arm is in 
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any way worse than the BCG alone arms. It is interesting that the majority of patients 
received maintenance therapy after developing recurrences, did not experience 
progression of disease. 
Conclusion 
There are many sound immunological reasons why the combination of BCG and IFNα 
should be better, not least because of their synergy in stimulating a cellular immune 
response, as summarized below.  
Fig. 47. Schema of how IFNα may modulate the effects of BCG 
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IFNα promotes development of TH0 cells towards a TH1 cellular immune response by 
increasing the production of IL-12 and IFNγ. It also increases T cell and NK cell 
cytotoxicity, inhibits “T suppressor cells” and increases MHC class I expression on 
target cells (Fig. 47).  
This priming of the cellular response elements is essential as mice deprived of CD4+ 
or CD8+ T cells or beige mice which are NK cell impaired do not demonstrate the 
anti-tumour effects of BCG (Ratliff et al 1993; Brandau et al 2001). The activated 
monocytes, CD4+ (T helper cells) and CD8+ (cytotoxic T cells) and NK cells contitute 
the effector arm of the anti-tumour response but this is possibly assisted and modulated 
by nitric oxide (NO) and cytokines from other sources including the tumour cells 
themselves. Expression of ICAM-1, MHC class I and II and other ligands are an 
important factor in effecting this anti-tumour response (Fig. 48). 
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Future studies 
Our current studies are directed at optimizing the schedules for BCG immunotherapy 
for patients who have previously received BCG immunotherapy and in developing 
cytokine gene therapy for bladder cancer, to assist non-responders whose immune 
systems are unable to mount an adequate TH1 cytokine response to BCG 
immunotherapy. This work is progressing well with the development of an effective 
gene delivery system for transfection of the urothelium and a novel orthotopic murine 
bladder cancer model (Lawrencia et al 2001; Wu et al 2003). 
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